Weeckee的个人主页 - 老虎社区

Weeckee

暂无个人介绍

IP属地：未知

486关注

29粉丝

0主题

0勋章

2021-12-21

Sure or not?

2 Top Healthcare Stocks Ready for a Bull Run in 2022

2021-12-20

Good

GM to extend production halt to EV Chevrolet Bolt through February

2021-12-19

Get yourself vaccinated

抱歉，原内容已删除

2021-12-18

Good lah. Help the people

Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list

2021-12-17

Does this mean stock will fly…but results do not seem so…

Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China

2021-12-16

Good if we had brought the share earlier

Shopify rallies after Evercore ISI calls out +25% upside potential

2021-12-14

Why are they falling?

EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3%

2021-12-13

Is this a buy?

Is Palantir a Buy?

2021-12-13

Hope so

Is Inflation Going to Cool Down Anytime Soon?

2021-12-11

Price going Up??

U.S. Cash Crude-Crude grades broadly rise at weekend

2021-12-11

Price will drop sure or not?

U.S. to sell 18 mln barrels of oil from reserves on Dec 17

2021-12-10

Apple still the favorite

Apple Nears $3 Trillion. Why It Could Still Be a Top Stock Pick for 2022.

2021-12-09

Apple apple Apple of my eye

Apple shares rose nearly 2% to a new high

2021-12-08

Good

Win Streak Expected To Continue For Singapore Stock Market

2021-12-08

Hope this will avert shortages of chips in future

Intel CEO aims to build chip plants with money raised from Mobileye IPO

2021-12-08

All talk to spook people and cause uneasiness. One minute good the next minute no good must have cocktails of vaccination… people are dead tired and need a break.

Study suggests Pfizer COVID-19 vaccine may only partially protect against Omicron

2021-12-07

Hope all is well

抱歉，原内容已删除

2021-12-07

People are still confused on the potency of the omicron virus. So mix feeling

Vaccine stocks mixed in morning trading

2021-12-06

Fly high high

Will Apple Stock Fly or Fall in 2022?

2021-12-05

Roller coaster for the daring soul who have extra cash.

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582072953259355,"uuid":"3582072953259355","gmtCreate":1618979146073,"gmtModify":1618979146073,"name":"Weeckee","pinyin":"weeckee","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":29,"headSize":486,"tweetSize":302,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.10","exceedPercentage":"60.18%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693472740,"gmtCreate":1640072008592,"gmtModify":1640072008920,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Sure or not?","listText":"Sure or not?","text":"Sure or not?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693472740","repostId":"2192184839","repostType":4,"repost":{"id":"2192184839","pubTimestamp":1640069892,"share":"https://www.laohu8.com/m/news/2192184839?lang=&edition=full","pubTime":"2021-12-21 14:58","market":"us","language":"en","title":"2 Top Healthcare Stocks Ready for a Bull Run in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2192184839","media":"Motley Fool","summary":"They've strongly outperformed the market in the past, and they could easily do it again.","content":"<p>There's nothing more exciting for me as an investor than when I notice that <a href=\"https://laohu8.com/S/AONE.U\">one</a> of my stocks is surging after finally getting its value recognized by the market. While there's no way to know for sure if a given stock has what it takes to outperform, looking at a company's upcoming catalysts is one trick that can help to stack the deck in your favor.</p>\n<p>In that vein, today I'll be discussing two healthcare businesses that have a few high-impact events coming in the near future. Assuming things break the way shareholders are hoping for, both could be off to a bull run next year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2c9dcbf97398f61aab8f8e888a48e6d\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals </b>(NASDAQ:CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%. And in the coming years, that revenue could grow even more.</p>\n<p>Now, Catalyst is focused on expanding Firdapse's approved indications to cover more populations of patients with LEMS, starting with children. At the same time, the company is developing an extended-release version of Firdapse, which will be preferable for patients and potentially command a higher selling price too. It's also working to commercialize Firdapse in Japan, starting early next year with a small registrational clinical trial that'll pave the way for larger investigations.</p>\n<p>Opening up new markets outside of the U.S. and Canada could be huge, as LEMS is so rare that only one in 100,000 people has it -- and Catalyst is the only company working on treatments. The main challenge will be finding markets where the disease is known enough to be consistently diagnosed. So, Catalyst's decision to target Japan is a good one, as the country has a high concentration of healthcare resources which should ensure that people with LEMS are both findable and treatable with Firdapse. Eventually, scaling the business to reach all of the LEMS patients in the entire world isn't something that's too far-fetched.</p>\n<p>Aside from its soon-to-be-expanding indications and its foray into foreign markets, the stock is priced to perfection. Its trailing price-to-earnings (PE) ratio is 18, which is vastly lower than the wider market's average near 30.</p>\n<p>The only question is: When will investors notice that this quiet stock is secretly a monster in the making?</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/52a6f20e558bda0a8b90dadb5622231a.png\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>^SPX data by YCharts</span></p>\n<h2>2. Vaxart</h2>\n<p><b>Vaxart </b>(NASDAQ:VXRT) is a small biotech that hasn't commercialized a product yet, but its oral coronavirus vaccine candidate just might be its first. And while the clinical trial process to evaluate the candidate takes place, there's still enough going on to push the stock into a bull run.</p>\n<p>The advantage of Vaxart's vaccine is that it's a pill rather than a jab. It's also shelf-stable and doesn't require an experienced healthcare worker to administer. As such, the pill could be a great fit for healthcare systems in resource-strapped areas, and it could even be sent to people by mail to reduce the care burden. Of course, that's assuming the candidate can make it through the rest of its clinical trials and be proven safe and effective.</p>\n<p>A favorable result from the vaccine pill's phase 2 trial would help to prove that its headliner oral vaccine technology is workable in the real world. As of now, the company's next planned data update is in the first quarter of 2022. Data derived from animal models in earlier experiments were largely positive, so a confirmation of those results in human subjects would be huge for shareholders.</p>\n<p>Vaxart is also advancing its pill for seasonal influenza, which concluded and reported its phase 2 trial results in January of 2020. Per the trial, its flu vaccine pill appears to be 39% effective at preventing symptoms, which is significantly better than the 27% effectiveness of one of the existing flu jabs on the market, Fluzone. Once Vaxart decides to move forward with its influenza pill, investors will have a chance to realize some upside upon the initiation and conclusion of its next clinical trials.</p>\n<p>It's important to remember that Vaxart is still a highly risky biotech stock, even if it could go on a tear in 2022. Clinical trials don't always go as planned, especially when there's a new technology in the mix.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Healthcare Stocks Ready for a Bull Run in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Healthcare Stocks Ready for a Bull Run in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/20/2-top-healthcare-stocks-ready-for-a-bull-run-in-20/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's nothing more exciting for me as an investor than when I notice that one of my stocks is surging after finally getting its value recognized by the market. While there's no way to know for sure ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/20/2-top-healthcare-stocks-ready-for-a-bull-run-in-20/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc","CPRX":"Catalyst Pharmaceutical Partners","BK4568":"美国抗疫概念","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2021/12/20/2-top-healthcare-stocks-ready-for-a-bull-run-in-20/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192184839","content_text":"There's nothing more exciting for me as an investor than when I notice that one of my stocks is surging after finally getting its value recognized by the market. While there's no way to know for sure if a given stock has what it takes to outperform, looking at a company's upcoming catalysts is one trick that can help to stack the deck in your favor.\nIn that vein, today I'll be discussing two healthcare businesses that have a few high-impact events coming in the near future. Assuming things break the way shareholders are hoping for, both could be off to a bull run next year.\nImage source: Getty Images.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%. And in the coming years, that revenue could grow even more.\nNow, Catalyst is focused on expanding Firdapse's approved indications to cover more populations of patients with LEMS, starting with children. At the same time, the company is developing an extended-release version of Firdapse, which will be preferable for patients and potentially command a higher selling price too. It's also working to commercialize Firdapse in Japan, starting early next year with a small registrational clinical trial that'll pave the way for larger investigations.\nOpening up new markets outside of the U.S. and Canada could be huge, as LEMS is so rare that only one in 100,000 people has it -- and Catalyst is the only company working on treatments. The main challenge will be finding markets where the disease is known enough to be consistently diagnosed. So, Catalyst's decision to target Japan is a good one, as the country has a high concentration of healthcare resources which should ensure that people with LEMS are both findable and treatable with Firdapse. Eventually, scaling the business to reach all of the LEMS patients in the entire world isn't something that's too far-fetched.\nAside from its soon-to-be-expanding indications and its foray into foreign markets, the stock is priced to perfection. Its trailing price-to-earnings (PE) ratio is 18, which is vastly lower than the wider market's average near 30.\nThe only question is: When will investors notice that this quiet stock is secretly a monster in the making?\n^SPX data by YCharts\n2. Vaxart\nVaxart (NASDAQ:VXRT) is a small biotech that hasn't commercialized a product yet, but its oral coronavirus vaccine candidate just might be its first. And while the clinical trial process to evaluate the candidate takes place, there's still enough going on to push the stock into a bull run.\nThe advantage of Vaxart's vaccine is that it's a pill rather than a jab. It's also shelf-stable and doesn't require an experienced healthcare worker to administer. As such, the pill could be a great fit for healthcare systems in resource-strapped areas, and it could even be sent to people by mail to reduce the care burden. Of course, that's assuming the candidate can make it through the rest of its clinical trials and be proven safe and effective.\nA favorable result from the vaccine pill's phase 2 trial would help to prove that its headliner oral vaccine technology is workable in the real world. As of now, the company's next planned data update is in the first quarter of 2022. Data derived from animal models in earlier experiments were largely positive, so a confirmation of those results in human subjects would be huge for shareholders.\nVaxart is also advancing its pill for seasonal influenza, which concluded and reported its phase 2 trial results in January of 2020. Per the trial, its flu vaccine pill appears to be 39% effective at preventing symptoms, which is significantly better than the 27% effectiveness of one of the existing flu jabs on the market, Fluzone. Once Vaxart decides to move forward with its influenza pill, investors will have a chance to realize some upside upon the initiation and conclusion of its next clinical trials.\nIt's important to remember that Vaxart is still a highly risky biotech stock, even if it could go on a tear in 2022. Clinical trials don't always go as planned, especially when there's a new technology in the mix.","news_type":1},"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693658398,"gmtCreate":1640015946182,"gmtModify":1640015946508,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693658398","repostId":"2192118051","repostType":4,"repost":{"id":"2192118051","pubTimestamp":1640013780,"share":"https://www.laohu8.com/m/news/2192118051?lang=&edition=full","pubTime":"2021-12-20 23:23","market":"us","language":"en","title":"GM to extend production halt to EV Chevrolet Bolt through February","url":"https://stock-news.laohu8.com/highlight/detail?id=2192118051","media":"StreetInsider","summary":"WASHINGTON, Dec 20  - General Motors Co said Monday it is extending a production halt at its Orion Assembly plant in Michigan, which makes the Chevrolet Bolt electric vehicle, through the end of February.The largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires. Earlier this month, it extended its production shutdown through late January. GM has also indefinitely halted retail sales of new Bolt vehicles.Th","content":"<p>WASHINGTON, Dec 20 (Reuters) - General Motors Co said Monday it is extending a production halt at its Orion Assembly plant in Michigan, which makes the Chevrolet Bolt electric vehicle, through the end of February.</p>\n<p>The largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires. Earlier this month, it extended its production shutdown through late January. GM has also indefinitely halted retail sales of new Bolt vehicles.</p>\n<p>The suburban Detroit plant halted production in August but conducted two weeks of limited production at Orion starting Nov. 1 to help provide courtesy transportation vehicles for customers during recall repairs.</p>\n<p>GM President Mark Reuss said in October the company was addressing the recall before resuming production. The company said Monday it will continue to prioritize recall repairs and \"focus on battery module replacements.\"</p>\n<p>The National Highway Traffic Safety Administration has an ongoing investigation into the battery fires. The agency noted in August that all Chevrolet Bolt electric vehicles had been recalled due to the risk of the high-voltage battery pack catching fire.</p>\n<p>GM disclosed in October that its battery partner, South Korea's LG Electronics, had agreed to reimburse it for the $2 billion in estimated costs and expenses associated with the Bolt recall.</p>\n<p>GM and LG Energy Solution are building two joint-venture U.S. battery plants. Reuters reported earlier this month GM has proposed building a $2.5 billion battery plant near Lansing with LG Energy Solution, citing documents filed with the city.</p>\n<p>The largest U.S. automaker is separately considering a $2 billion overhaul of its Orion Township assembly plant north of Detroit to build next-generation electric vehicles. The total investments could top $4 billion, a source familiar with the plan told Reuters.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GM to extend production halt to EV Chevrolet Bolt through February</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGM to extend production halt to EV Chevrolet Bolt through February\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 23:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19372864><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON, Dec 20 (Reuters) - General Motors Co said Monday it is extending a production halt at its Orion Assembly plant in Michigan, which makes the Chevrolet Bolt electric vehicle, through the end...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19372864\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4099":"汽车制造商","BK4555":"新能源车","BK4559":"巴菲特持仓","BK4561":"索罗斯持仓","GM":"通用汽车"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19372864","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192118051","content_text":"WASHINGTON, Dec 20 (Reuters) - General Motors Co said Monday it is extending a production halt at its Orion Assembly plant in Michigan, which makes the Chevrolet Bolt electric vehicle, through the end of February.\nThe largest U.S. automaker in August widened its recall of the Bolt to more than 140,000 vehicles to replace battery modules after a series of fires. Earlier this month, it extended its production shutdown through late January. GM has also indefinitely halted retail sales of new Bolt vehicles.\nThe suburban Detroit plant halted production in August but conducted two weeks of limited production at Orion starting Nov. 1 to help provide courtesy transportation vehicles for customers during recall repairs.\nGM President Mark Reuss said in October the company was addressing the recall before resuming production. The company said Monday it will continue to prioritize recall repairs and \"focus on battery module replacements.\"\nThe National Highway Traffic Safety Administration has an ongoing investigation into the battery fires. The agency noted in August that all Chevrolet Bolt electric vehicles had been recalled due to the risk of the high-voltage battery pack catching fire.\nGM disclosed in October that its battery partner, South Korea's LG Electronics, had agreed to reimburse it for the $2 billion in estimated costs and expenses associated with the Bolt recall.\nGM and LG Energy Solution are building two joint-venture U.S. battery plants. Reuters reported earlier this month GM has proposed building a $2.5 billion battery plant near Lansing with LG Energy Solution, citing documents filed with the city.\nThe largest U.S. automaker is separately considering a $2 billion overhaul of its Orion Township assembly plant north of Detroit to build next-generation electric vehicles. The total investments could top $4 billion, a source familiar with the plan told Reuters.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693002445,"gmtCreate":1639919653697,"gmtModify":1639919654073,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Get yourself vaccinated&nbsp;","listText":"Get yourself vaccinated&nbsp;","text":"Get yourself vaccinated","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693002445","repostId":"2192790540","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699820204,"gmtCreate":1639783010615,"gmtModify":1639783010984,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good lah. Help the people","listText":"Good lah. Help the people","text":"Good lah. Help the people","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699820204","repostId":"1155244596","repostType":4,"repost":{"id":"1155244596","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752003,"share":"https://www.laohu8.com/m/news/1155244596?lang=&edition=full","pubTime":"2021-12-17 22:40","market":"us","language":"en","title":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list","url":"https://stock-news.laohu8.com/highlight/detail?id=1155244596","media":"Tiger Newspress","summary":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emerg","content":"<p>Novavax continued to jump nearly&nbsp;5% in morning trading as its vaccine had been included on the&nbsp;emergency use list.<img src=\"https://static.tigerbbs.com/6e0b5588f7377a98c70179cdc8612b3f\" tg-width=\"765\" tg-height=\"561\" width=\"100%\" height=\"auto\">The World Health Organization has included&nbsp;its&nbsp;vaccine NVX-CoV2373 on the emergency use list,and its&nbsp;original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax continued to jump nearly&nbsp;5% in morning trading as its vaccine had been included on the&nbsp;emergency use list.<img src=\"https://static.tigerbbs.com/6e0b5588f7377a98c70179cdc8612b3f\" tg-width=\"765\" tg-height=\"561\" width=\"100%\" height=\"auto\">The World Health Organization has included&nbsp;its&nbsp;vaccine NVX-CoV2373 on the emergency use list,and its&nbsp;original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155244596","content_text":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list.The World Health Organization has included its vaccine NVX-CoV2373 on the emergency use list,and its original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.","news_type":1},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699383353,"gmtCreate":1639749416698,"gmtModify":1639749417061,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Does this mean stock will fly…but results do not seem so…","listText":"Does this mean stock will fly…but results do not seem so…","text":"Does this mean stock will fly…but results do not seem so…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699383353","repostId":"2192462941","repostType":4,"repost":{"id":"2192462941","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639724284,"share":"https://www.laohu8.com/m/news/2192462941?lang=&edition=full","pubTime":"2021-12-17 14:58","market":"us","language":"en","title":"Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2192462941","media":"Investors","summary":"A smaller electric sedan could be Tesla rival's most affordable and 'highest volume' electric vehicle yet.","content":"<p><b>Nio</b> is poised to unleash its newest electric vehicle — one that could threaten the <b>Tesla</b> Model 3 in China, while kick-starting Nio stock back to life.</p>\n<p>Ahead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.</p>\n<p>Like many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.</p>\n<p>In a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.</p>\n<p>That's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.</p>\n<p>In his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.</p>\n<p>Nio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.</p>\n<h2>Nio Stock, EV Stocks</h2>\n<p>Shares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, <b>Xpeng</b> fell 2.1% and <b>Li Auto</b> slumped 1.5%.</p>\n<p>For Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.</p>\n<p>\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.</p>\n<p>At Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.</p>\n<p>In September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-12-17 14:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Nio</b> is poised to unleash its newest electric vehicle — one that could threaten the <b>Tesla</b> Model 3 in China, while kick-starting Nio stock back to life.</p>\n<p>Ahead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.</p>\n<p>Like many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.</p>\n<p>In a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.</p>\n<p>That's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.</p>\n<p>In his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.</p>\n<p>Nio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.</p>\n<h2>Nio Stock, EV Stocks</h2>\n<p>Shares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, <b>Xpeng</b> fell 2.1% and <b>Li Auto</b> slumped 1.5%.</p>\n<p>For Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.</p>\n<p>\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.</p>\n<p>At Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.</p>\n<p>In September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4124":"机动车零配件与设备","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192462941","content_text":"Nio is poised to unleash its newest electric vehicle — one that could threaten the Tesla Model 3 in China, while kick-starting Nio stock back to life.\nAhead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.\nLike many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.\nIn a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.\nThat's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.\nIn his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.\nNio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.\nNio Stock, EV Stocks\nShares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, Xpeng fell 2.1% and Li Auto slumped 1.5%.\nFor Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.\n\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.\nAt Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.\nIn September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.","news_type":1},"isVote":1,"tweetType":1,"viewCount":493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690856288,"gmtCreate":1639657592879,"gmtModify":1639657593231,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good if we had brought the share earlier&nbsp;","listText":"Good if we had brought the share earlier&nbsp;","text":"Good if we had brought the share earlier","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690856288","repostId":"1122700546","repostType":4,"repost":{"id":"1122700546","pubTimestamp":1639656448,"share":"https://www.laohu8.com/m/news/1122700546?lang=&edition=full","pubTime":"2021-12-16 20:07","market":"us","language":"en","title":"Shopify rallies after Evercore ISI calls out +25% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1122700546","media":"Seeking Alpha","summary":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.","content":"<ul>\n <li>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.</li>\n <li>Analyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.</li>\n <li>Shares of SHOP are&nbsp;up 3.08%&nbsp;in premarket action to $1,410.26.</li>\n <li>Evercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the&nbsp;average Wall Street PT of $1,698.19.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shopify rallies after Evercore ISI calls out +25% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShopify rallies after Evercore ISI calls out +25% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/...</p>\n\n<a href=\"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SHOP":"Shopify Inc"},"source_url":"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122700546","content_text":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.\nShares of SHOP are up 3.08% in premarket action to $1,410.26.\nEvercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the average Wall Street PT of $1,698.19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604499478,"gmtCreate":1639436254792,"gmtModify":1639436255102,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Why are they falling?","listText":"Why are they falling?","text":"Why are they falling?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604499478","repostId":"1125628300","repostType":4,"repost":{"id":"1125628300","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639408702,"share":"https://www.laohu8.com/m/news/1125628300?lang=&edition=full","pubTime":"2021-12-13 23:18","market":"us","language":"en","title":"EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3% ","url":"https://stock-news.laohu8.com/highlight/detail?id=1125628300","media":"Tiger Newspress","summary":"EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling aro","content":"<p>EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3%.<img src=\"https://static.tigerbbs.com/339c507942577109dbbbb0437dd2eb2d\" tg-width=\"537\" tg-height=\"197\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3% \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3%.<img src=\"https://static.tigerbbs.com/339c507942577109dbbbb0437dd2eb2d\" tg-width=\"537\" tg-height=\"197\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","LI":"理想汽车","GM":"通用汽车","F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125628300","content_text":"EV stocks slid in morning trading, with Tesla falling over 4%,and Li,General motors,Ford falling around 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604699011,"gmtCreate":1639381169787,"gmtModify":1639381440631,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Is this a buy?","listText":"Is this a buy?","text":"Is this a buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604699011","repostId":"2190067720","repostType":4,"repost":{"id":"2190067720","pubTimestamp":1639380246,"share":"https://www.laohu8.com/m/news/2190067720?lang=&edition=full","pubTime":"2021-12-13 15:24","market":"us","language":"en","title":"Is Palantir a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190067720","media":"Motley Fool","summary":"This artificial intelligence stock has been mission-critical to government operations, but is it mission-critical to your portfolio?","content":"<p>When companies create vast amounts of data, much of the data they produce is unstructured -- meaning the data cannot fit neatly onto a spreadsheet. Nearly 90% of all data created is unstructured, and the amount of that data type has grown at 60% annually according to Bernard Marr &amp; Co.</p>\n<p>Because this kind of data can be difficult to analyze, it's harder for businesses to fully understand and integrate it into their actions and operations. Governments felt the same magnified problem on their battlefields. Then, along came<b> Palantir</b> (NYSE:PLTR), a software company that provided capabilities for the U.S. government and its allies. Palantir's platform, Gotham, helps military and intelligence agencies analyze data and identify patterns hidden deep within datasets. There is no doubt that this company is doing important things, but is it worth a purchase by the average investor?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c65ccdeefc7f3f9fc9aec23b6b0305ff\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Building strong relationships</h2>\n<p>Palantir has become known as a safe, secure, and powerful analytics platform among the U.S. government and its allies. Having various sectors of the U.S. government like the Army and CIA as customers is a powerful testament to the security and reliability of Palantir.&nbsp;Palantir was even rumored to help capture Osama Bin Laden in 2011. This achievement helped in its efforts to move into the private sector.</p>\n<p>For a long time, Palantir worked exclusively for the government, and it only recently expanded its offering -- Foundry -- to the private sector in 2016. However, Palantir is already seeing tons of success in this shift. The company has grown its revenue from the commercial sector by 103% year over year, and the company's customer count has doubled since the start of the year and grew 46% sequentially.</p>\n<p>This rapid adoption from the commercial sector is important because Palantir's software is extremely sticky and it is very expensive to obtain customers. The company spent over $150 million in sales and marketing in the third quarter of 2021, representing almost 40% of its revenue. As a result, Palantir brought in 54 deals. While 54 deals don't seem like a lot, 51 of those deals are worth $5 million or more, and 18 of those are worth more than $10 million.</p>\n<p>With deals this expensive, once you become a customer, it is probable that you are going to stay a customer -- that's stickiness. Not only because of the price but also because Palantir's services can quickly become an integral part that businesses rely on. Therefore, this rapid adoption from the commercial sector is a great sign that Palantir will continue to succeed in this space. This is crucial to the company, since Palantir's customer concentration currently shows it's still massively reliant on the government for business.</p>\n<p>The company only has a total of 203 customers, and over half of its revenue comes from government clients. This likely comes from heavy U.S. government concentration from various government agencies&nbsp;While no exact concentration figures from the total U.S. government are given, 10% of revenue in 2020 came from <a href=\"https://laohu8.com/S/AONE.U\">one</a> government branch.</p>\n<h2>The key risks</h2>\n<p>Aside from the immense reliance on the government, there are other risks associated with Palantir's business. Especially with the government, security is a major concern. While Palantir has never had any security breaches yet, all it takes is <i>one</i> for the relationship it has built with a major government customer to dissipate. Palantir prides itself on its security and ability to hold sensitive information, and any failure to do so could wreck the company.</p>\n<p>A second risk is the company's path to profitability.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th></th>\n   <th>Q3 2021</th>\n   <th>Q3 2020</th>\n   <th>Change</th>\n  </tr>\n  <tr>\n   <td>Net Loss</td>\n   <td>$102 million</td>\n   <td>$853 million</td>\n   <td>(88%)</td>\n  </tr>\n  <tr>\n   <td>Net Loss as a Percentage of Revenue</td>\n   <td>26%</td>\n   <td>295%</td>\n   <td>N/A</td>\n  </tr>\n </tbody>\n</table>\n<p>Source: Palantir Company Filings.</p>\n<p>The company's losses haven't been pretty, but they have dramatically improved from the year-ago quarter. This has been helped in part by Palantir's success in the commercial sector, and while it has been expensive to market and gain customers in this part of the industry, the company has been extremely successful so far. If the company can continue to attract commercial customers, this net loss will likely improve substantially. If this cannot happen, however, the company could fail to become profitable and hurt investors for the long term.</p>\n<h2>Is it a buy?</h2>\n<p>Palantir is not a stock for every investor, as it still carries some risk. However, the thesis behind this company relies on its ability to integrate itself into the commercial sector, and its superior product is, so far, doing just that. The company is not cheap while trading at 25 times sales, but for investors who have a diversified portfolio that allows them to make a few risky bets, this company has the potential to make the shortlist.</p>\n<p>I own Palantir for two reasons. First, I love what it is doing for the world. Palantir's technology allows government entities to analyze and notice things they have never been able to before, and I believe that is making me -- an American citizen -- safer. Second, I love technology. Both Gotham and Foundry are innovative solutions that use artificial intelligence to unlock a whole new world of data -- which is something that hasn't been done at scale before, and that is fascinating. If these two things matter to you, then you might want to look into putting Palantir in a diversified portfolio. However, if you are an investor who cannot take on as much risk, this company might not be for you.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Palantir a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Palantir a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 15:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/is-palantir-a-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When companies create vast amounts of data, much of the data they produce is unstructured -- meaning the data cannot fit neatly onto a spreadsheet. Nearly 90% of all data created is unstructured, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/is-palantir-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4547":"WSB热门概念","PLTR":"Palantir Technologies Inc.","BK4023":"应用软件","BK4543":"AI"},"source_url":"https://www.fool.com/investing/2021/12/12/is-palantir-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190067720","content_text":"When companies create vast amounts of data, much of the data they produce is unstructured -- meaning the data cannot fit neatly onto a spreadsheet. Nearly 90% of all data created is unstructured, and the amount of that data type has grown at 60% annually according to Bernard Marr & Co.\nBecause this kind of data can be difficult to analyze, it's harder for businesses to fully understand and integrate it into their actions and operations. Governments felt the same magnified problem on their battlefields. Then, along came Palantir (NYSE:PLTR), a software company that provided capabilities for the U.S. government and its allies. Palantir's platform, Gotham, helps military and intelligence agencies analyze data and identify patterns hidden deep within datasets. There is no doubt that this company is doing important things, but is it worth a purchase by the average investor?\nImage source: Getty Images.\nBuilding strong relationships\nPalantir has become known as a safe, secure, and powerful analytics platform among the U.S. government and its allies. Having various sectors of the U.S. government like the Army and CIA as customers is a powerful testament to the security and reliability of Palantir. Palantir was even rumored to help capture Osama Bin Laden in 2011. This achievement helped in its efforts to move into the private sector.\nFor a long time, Palantir worked exclusively for the government, and it only recently expanded its offering -- Foundry -- to the private sector in 2016. However, Palantir is already seeing tons of success in this shift. The company has grown its revenue from the commercial sector by 103% year over year, and the company's customer count has doubled since the start of the year and grew 46% sequentially.\nThis rapid adoption from the commercial sector is important because Palantir's software is extremely sticky and it is very expensive to obtain customers. The company spent over $150 million in sales and marketing in the third quarter of 2021, representing almost 40% of its revenue. As a result, Palantir brought in 54 deals. While 54 deals don't seem like a lot, 51 of those deals are worth $5 million or more, and 18 of those are worth more than $10 million.\nWith deals this expensive, once you become a customer, it is probable that you are going to stay a customer -- that's stickiness. Not only because of the price but also because Palantir's services can quickly become an integral part that businesses rely on. Therefore, this rapid adoption from the commercial sector is a great sign that Palantir will continue to succeed in this space. This is crucial to the company, since Palantir's customer concentration currently shows it's still massively reliant on the government for business.\nThe company only has a total of 203 customers, and over half of its revenue comes from government clients. This likely comes from heavy U.S. government concentration from various government agencies While no exact concentration figures from the total U.S. government are given, 10% of revenue in 2020 came from one government branch.\nThe key risks\nAside from the immense reliance on the government, there are other risks associated with Palantir's business. Especially with the government, security is a major concern. While Palantir has never had any security breaches yet, all it takes is one for the relationship it has built with a major government customer to dissipate. Palantir prides itself on its security and ability to hold sensitive information, and any failure to do so could wreck the company.\nA second risk is the company's path to profitability.\n\n\n\n\nQ3 2021\nQ3 2020\nChange\n\n\nNet Loss\n$102 million\n$853 million\n(88%)\n\n\nNet Loss as a Percentage of Revenue\n26%\n295%\nN/A\n\n\n\nSource: Palantir Company Filings.\nThe company's losses haven't been pretty, but they have dramatically improved from the year-ago quarter. This has been helped in part by Palantir's success in the commercial sector, and while it has been expensive to market and gain customers in this part of the industry, the company has been extremely successful so far. If the company can continue to attract commercial customers, this net loss will likely improve substantially. If this cannot happen, however, the company could fail to become profitable and hurt investors for the long term.\nIs it a buy?\nPalantir is not a stock for every investor, as it still carries some risk. However, the thesis behind this company relies on its ability to integrate itself into the commercial sector, and its superior product is, so far, doing just that. The company is not cheap while trading at 25 times sales, but for investors who have a diversified portfolio that allows them to make a few risky bets, this company has the potential to make the shortlist.\nI own Palantir for two reasons. First, I love what it is doing for the world. Palantir's technology allows government entities to analyze and notice things they have never been able to before, and I believe that is making me -- an American citizen -- safer. Second, I love technology. Both Gotham and Foundry are innovative solutions that use artificial intelligence to unlock a whole new world of data -- which is something that hasn't been done at scale before, and that is fascinating. If these two things matter to you, then you might want to look into putting Palantir in a diversified portfolio. However, if you are an investor who cannot take on as much risk, this company might not be for you.","news_type":1},"isVote":1,"tweetType":1,"viewCount":682,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604392092,"gmtCreate":1639333913127,"gmtModify":1639333913472,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope so","listText":"Hope so","text":"Hope so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604392092","repostId":"2190719916","repostType":4,"repost":{"id":"2190719916","pubTimestamp":1639280175,"share":"https://www.laohu8.com/m/news/2190719916?lang=&edition=full","pubTime":"2021-12-12 11:36","market":"us","language":"en","title":"Is Inflation Going to Cool Down Anytime Soon?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190719916","media":"Motley Fool","summary":"Two Motley Fool contributors discuss the issue weighing on a lot of people's minds.","content":"<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of<i> Backstage Pass</i>, recorded on <b>Nov. 10</b>, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.</p>\n<p><b>Connor Allen</b>: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.</p>\n<p>Because when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.</p>\n<p>Gas is <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like <b>Amazon</b>, whether it's delivered to a retail store like <b>Macy's</b>, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.</p>\n<p>That's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.</p>\n<p>That could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.</p>\n<p><b>Rachel Warren:</b> I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.</p>\n<p>I think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.</p>\n<p>I saw this interesting article on <i>CNBC</i> today and the Chief Financial Officer of a large Belgian Dutch grocer called <b>Ahold Delhaize</b> was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"</p>\n<p>Another thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of <b>Siemens</b> <b>Energy</b> told <i>CNBC</i>, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.</p>\n<p>As a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.</p>\n<p>Maybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.</p>\n<p>Recently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Inflation Going to Cool Down Anytime Soon?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Inflation Going to Cool Down Anytime Soon?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190719916","content_text":"Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of Backstage Pass, recorded on Nov. 10, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.\nConnor Allen: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.\nBecause when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.\nGas is one that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like Amazon, whether it's delivered to a retail store like Macy's, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.\nThat's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.\nThat could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.\nRachel Warren: I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.\nI think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.\nI saw this interesting article on CNBC today and the Chief Financial Officer of a large Belgian Dutch grocer called Ahold Delhaize was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"\nAnother thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of Siemens Energy told CNBC, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.\nAs a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.\nMaybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.\nRecently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605466232,"gmtCreate":1639221818284,"gmtModify":1639221885303,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Price going Up??","listText":"Price going Up??","text":"Price going Up??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605466232","repostId":"2190678761","repostType":4,"repost":{"id":"2190678761","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639172370,"share":"https://www.laohu8.com/m/news/2190678761?lang=&edition=full","pubTime":"2021-12-11 05:39","market":"us","language":"en","title":"U.S. Cash Crude-Crude grades broadly rise at weekend","url":"https://stock-news.laohu8.com/highlight/detail?id=2190678761","media":"Reuters","summary":"Dec 10 (Reuters) - U.S. crude grades broadly rose on Friday, dealers said, as U.S. crude's discount ","content":"<p>Dec 10 (Reuters) - U.S. crude grades broadly rose on Friday, dealers said, as U.S. crude's discount to Brent widened.</p>\n<p>The WTI/Brent spread widened to minus-$3.67 per barrel, after settling at minus-$3.63 the day before. A wider spread typically makes U.S. crude-linked grades more attractive to foreign buyers, while the narrowing spread favors Brent-linked crudes.</p>\n<p>U.S. oil rigs rose four to 471 this week, their highest since April 2020, energy services firm Baker Hughes Co said on Friday.</p>\n<p>In the futures market, crude prices rose slightly and were on track for their biggest weekly gain since late August, with market sentiment buoyed by easing concerns over the Omicron coronavirus variant's impact on global economic growth and fuel demand.</p>\n<p>In the refining sector, <a href=\"https://laohu8.com/S/RYDAF\">Royal Dutch Shell Plc</a> was restarting on Friday the crude distillation unit <a href=\"https://laohu8.com/S/CDU.AU\">$(CDU.AU)$</a> at its 230,811 barrel-per-day (bpd) Norco, Louisiana, refinery after completing repairs from Hurricane Ida, said sources familiar with plant operations.</p>\n<p>* Light Louisiana Sweet for January delivery rose 85 cents to a midpoint of $2.25 and traded between $2.15 and $2.35 a barrel premium to U.S. crude futures .</p>\n<p>* Mars Sour rose 50 cents to a midpoint of flat and traded between a 10-cent discount and a 10-cent premium to U.S. crude futures .</p>\n<p>* WTI Midland rose 10 cents to a midpoint of 85 cents and traded between 75 cents and 95 cents premium to U.S. crude futures .</p>\n<p>* West Texas Sour rose 95 cents to a midpoint of 35 cents and traded between 25 cents and 45 cents discount to U.S. crude futures .</p>\n<p>* WTI at East Houston, also known as MEH, traded at $1.35 over WTI.</p>\n<p>* ICE Brent February futures rose 73 cents to settle at $75.15 a barrel.</p>\n<p>* WTI January crude futures rose $0.73 to settle at $71.67 a barrel.</p>\n<p>* The Brent/WTI spread widened 4 cents to settle at minus-$3.67, after hitting a high of minus-$3.44 and a low of minus-$3.71.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Cash Crude-Crude grades broadly rise at weekend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Cash Crude-Crude grades broadly rise at weekend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-11 05:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 10 (Reuters) - U.S. crude grades broadly rose on Friday, dealers said, as U.S. crude's discount to Brent widened.</p>\n<p>The WTI/Brent spread widened to minus-$3.67 per barrel, after settling at minus-$3.63 the day before. A wider spread typically makes U.S. crude-linked grades more attractive to foreign buyers, while the narrowing spread favors Brent-linked crudes.</p>\n<p>U.S. oil rigs rose four to 471 this week, their highest since April 2020, energy services firm Baker Hughes Co said on Friday.</p>\n<p>In the futures market, crude prices rose slightly and were on track for their biggest weekly gain since late August, with market sentiment buoyed by easing concerns over the Omicron coronavirus variant's impact on global economic growth and fuel demand.</p>\n<p>In the refining sector, <a href=\"https://laohu8.com/S/RYDAF\">Royal Dutch Shell Plc</a> was restarting on Friday the crude distillation unit <a href=\"https://laohu8.com/S/CDU.AU\">$(CDU.AU)$</a> at its 230,811 barrel-per-day (bpd) Norco, Louisiana, refinery after completing repairs from Hurricane Ida, said sources familiar with plant operations.</p>\n<p>* Light Louisiana Sweet for January delivery rose 85 cents to a midpoint of $2.25 and traded between $2.15 and $2.35 a barrel premium to U.S. crude futures .</p>\n<p>* Mars Sour rose 50 cents to a midpoint of flat and traded between a 10-cent discount and a 10-cent premium to U.S. crude futures .</p>\n<p>* WTI Midland rose 10 cents to a midpoint of 85 cents and traded between 75 cents and 95 cents premium to U.S. crude futures .</p>\n<p>* West Texas Sour rose 95 cents to a midpoint of 35 cents and traded between 25 cents and 45 cents discount to U.S. crude futures .</p>\n<p>* WTI at East Houston, also known as MEH, traded at $1.35 over WTI.</p>\n<p>* ICE Brent February futures rose 73 cents to settle at $75.15 a barrel.</p>\n<p>* WTI January crude futures rose $0.73 to settle at $71.67 a barrel.</p>\n<p>* The Brent/WTI spread widened 4 cents to settle at minus-$3.67, after hitting a high of minus-$3.44 and a low of minus-$3.71.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UCO":"二倍做多彭博原油ETF","DWT":"三倍做空原油ETN","DUG":"二倍做空石油与天然气ETF(ProShares)","DDG":"ProShares做空石油与天然气ETF","SCO":"二倍做空彭博原油指数ETF","USO":"美国原油ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190678761","content_text":"Dec 10 (Reuters) - U.S. crude grades broadly rose on Friday, dealers said, as U.S. crude's discount to Brent widened.\nThe WTI/Brent spread widened to minus-$3.67 per barrel, after settling at minus-$3.63 the day before. A wider spread typically makes U.S. crude-linked grades more attractive to foreign buyers, while the narrowing spread favors Brent-linked crudes.\nU.S. oil rigs rose four to 471 this week, their highest since April 2020, energy services firm Baker Hughes Co said on Friday.\nIn the futures market, crude prices rose slightly and were on track for their biggest weekly gain since late August, with market sentiment buoyed by easing concerns over the Omicron coronavirus variant's impact on global economic growth and fuel demand.\nIn the refining sector, Royal Dutch Shell Plc was restarting on Friday the crude distillation unit $(CDU.AU)$ at its 230,811 barrel-per-day (bpd) Norco, Louisiana, refinery after completing repairs from Hurricane Ida, said sources familiar with plant operations.\n* Light Louisiana Sweet for January delivery rose 85 cents to a midpoint of $2.25 and traded between $2.15 and $2.35 a barrel premium to U.S. crude futures .\n* Mars Sour rose 50 cents to a midpoint of flat and traded between a 10-cent discount and a 10-cent premium to U.S. crude futures .\n* WTI Midland rose 10 cents to a midpoint of 85 cents and traded between 75 cents and 95 cents premium to U.S. crude futures .\n* West Texas Sour rose 95 cents to a midpoint of 35 cents and traded between 25 cents and 45 cents discount to U.S. crude futures .\n* WTI at East Houston, also known as MEH, traded at $1.35 over WTI.\n* ICE Brent February futures rose 73 cents to settle at $75.15 a barrel.\n* WTI January crude futures rose $0.73 to settle at $71.67 a barrel.\n* The Brent/WTI spread widened 4 cents to settle at minus-$3.67, after hitting a high of minus-$3.44 and a low of minus-$3.71.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1099,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605466361,"gmtCreate":1639221758329,"gmtModify":1639221916791,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Price will drop sure or not?","listText":"Price will drop sure or not?","text":"Price will drop sure or not?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605466361","repostId":"2190673907","repostType":4,"repost":{"id":"2190673907","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639173100,"share":"https://www.laohu8.com/m/news/2190673907?lang=&edition=full","pubTime":"2021-12-11 05:51","market":"us","language":"en","title":"U.S. to sell 18 mln barrels of oil from reserves on Dec 17","url":"https://stock-news.laohu8.com/highlight/detail?id=2190673907","media":"Reuters","summary":"Dec 10 (Reuters) - The U.S. Department of Energy said on Friday it will sell 18 million barrels of c","content":"<p>Dec 10 (Reuters) - The U.S. Department of Energy said on Friday it will sell 18 million barrels of crude oil from its strategic petroleum reserve <a href=\"https://laohu8.com/S/SPR\">$(SPR)$</a> on Dec. 17, as part of a previously announced plan to try to reduce oil prices.</p>\n<p>The Biden Administration announced last month it would release about 50 million barrels from its reserves in conjunction with other countries to combat the rising cost of fuel.</p>\n<p>The White House has been trying to deal with Americans' worries about high fuel costs, even though the president has few tools to deal with the price of crude, a global market influenced by numerous factors.</p>\n<p>“The President rightly believes Americans deserve relief now and has authorized the use of the SPR to respond to market imbalances and reduce costs for consumers,\" said  Energy Secretary Jennifer Granholm.</p>\n<p>Oil prices rose to seven-year highs at more than $86 a barrel due to surging fuel demand worldwide, but have dropped by nearly 13% since late October, in part due to the U.S. announcement and the emergence of the Omicron variant of coronavirus that has dented travel around the world.</p>\n<p>The Brent benchmark ended at $75.15 a barrel on Friday.</p>\n<p>The 18 million barrels to be sold had already been approved by Congress in 2018. The remaining barrels will be issued in coming months through exchanges. The first exchange of 4.8 million barrels will be with Exxon Mobil Corp , the largest U.S. oil company.</p>\n<p>U.S. retail gas prices are currently averaging $3.33 a gallon, the lowest since mid-October, according to the American Automobile Association. Prices peaked at $3.42 a gallon early in November.</p>\n<p>The United States holds roughly 600 million barrels of crude oil in giant caverns in Texas and Louisiana. Its current inventory is at its lowest since 2003.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. to sell 18 mln barrels of oil from reserves on Dec 17</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. to sell 18 mln barrels of oil from reserves on Dec 17\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-11 05:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 10 (Reuters) - The U.S. Department of Energy said on Friday it will sell 18 million barrels of crude oil from its strategic petroleum reserve <a href=\"https://laohu8.com/S/SPR\">$(SPR)$</a> on Dec. 17, as part of a previously announced plan to try to reduce oil prices.</p>\n<p>The Biden Administration announced last month it would release about 50 million barrels from its reserves in conjunction with other countries to combat the rising cost of fuel.</p>\n<p>The White House has been trying to deal with Americans' worries about high fuel costs, even though the president has few tools to deal with the price of crude, a global market influenced by numerous factors.</p>\n<p>“The President rightly believes Americans deserve relief now and has authorized the use of the SPR to respond to market imbalances and reduce costs for consumers,\" said  Energy Secretary Jennifer Granholm.</p>\n<p>Oil prices rose to seven-year highs at more than $86 a barrel due to surging fuel demand worldwide, but have dropped by nearly 13% since late October, in part due to the U.S. announcement and the emergence of the Omicron variant of coronavirus that has dented travel around the world.</p>\n<p>The Brent benchmark ended at $75.15 a barrel on Friday.</p>\n<p>The 18 million barrels to be sold had already been approved by Congress in 2018. The remaining barrels will be issued in coming months through exchanges. The first exchange of 4.8 million barrels will be with Exxon Mobil Corp , the largest U.S. oil company.</p>\n<p>U.S. retail gas prices are currently averaging $3.33 a gallon, the lowest since mid-October, according to the American Automobile Association. Prices peaked at $3.42 a gallon early in November.</p>\n<p>The United States holds roughly 600 million barrels of crude oil in giant caverns in Texas and Louisiana. Its current inventory is at its lowest since 2003.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4187":"航天航空与国防","XOM":"埃克森美孚","BK4201":"综合性石油与天然气企业","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","SPR":"Spirit AeroSystems Holdings Inc","BK4516":"特朗普概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190673907","content_text":"Dec 10 (Reuters) - The U.S. Department of Energy said on Friday it will sell 18 million barrels of crude oil from its strategic petroleum reserve $(SPR)$ on Dec. 17, as part of a previously announced plan to try to reduce oil prices.\nThe Biden Administration announced last month it would release about 50 million barrels from its reserves in conjunction with other countries to combat the rising cost of fuel.\nThe White House has been trying to deal with Americans' worries about high fuel costs, even though the president has few tools to deal with the price of crude, a global market influenced by numerous factors.\n“The President rightly believes Americans deserve relief now and has authorized the use of the SPR to respond to market imbalances and reduce costs for consumers,\" said  Energy Secretary Jennifer Granholm.\nOil prices rose to seven-year highs at more than $86 a barrel due to surging fuel demand worldwide, but have dropped by nearly 13% since late October, in part due to the U.S. announcement and the emergence of the Omicron variant of coronavirus that has dented travel around the world.\nThe Brent benchmark ended at $75.15 a barrel on Friday.\nThe 18 million barrels to be sold had already been approved by Congress in 2018. The remaining barrels will be issued in coming months through exchanges. The first exchange of 4.8 million barrels will be with Exxon Mobil Corp , the largest U.S. oil company.\nU.S. retail gas prices are currently averaging $3.33 a gallon, the lowest since mid-October, according to the American Automobile Association. Prices peaked at $3.42 a gallon early in November.\nThe United States holds roughly 600 million barrels of crude oil in giant caverns in Texas and Louisiana. Its current inventory is at its lowest since 2003.","news_type":1},"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605865261,"gmtCreate":1639146088359,"gmtModify":1639146089327,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Apple still the favorite&nbsp;","listText":"Apple still the favorite&nbsp;","text":"Apple still the favorite","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605865261","repostId":"1169522079","repostType":4,"repost":{"id":"1169522079","pubTimestamp":1639136423,"share":"https://www.laohu8.com/m/news/1169522079?lang=&edition=full","pubTime":"2021-12-10 19:40","market":"us","language":"en","title":"Apple Nears $3 Trillion. Why It Could Still Be a Top Stock Pick for 2022.","url":"https://stock-news.laohu8.com/highlight/detail?id=1169522079","media":"Barrons","summary":"Apple is a top stock pick for Morgan Stanley in 2022 as the tech giant nears a $3 trillion market ca","content":"<p>Apple&nbsp;is a top stock pick for Morgan Stanley in 2022 as the tech giant nears a $3 trillion market capitalization and prepares to launch an augmented reality product.</p>\n<p>“The combination of a strong, loyal customer base and the upcoming launch of AR/VR products positions AAPL for a re-rating in 2022,” analyst Katy Huberty wrote in a note Thursday. Huberty wrote that Apple was Morgan Stanley’s “favorite large cap (and overall Top Pick)” heading into 2022.</p>\n<p>Huberty’s call comes two days after she reiterated an Overweight rating on shares of Apple (ticker: AAPL) and raised her price target 21% to $200 from $164.</p>\n<p>Apple shares were rising 0.2% to $175.47 on Thursday. The stock has risen about 32% this year, reaching a market capitalization of $2.87 trillion. Over the last month, it has jumped 19%, outperforming the&nbsp;Dow Jones Industrial Average’s&nbsp;0.5% rise, the&nbsp;S&amp;P 500’s&nbsp;0.9% gain, and the&nbsp;Nasdaq Composite’s&nbsp;0.04% advance.</p>\n<p>Morgan Stanley believes investors should value Apple as a consumer and technology platform rather than a cyclical hardware company, given that around a third of gross profits come from the company’s services segment. iPhone 13 demand will continue to drive growth in the short term, with new product launches in early 2022 continuing the trend, Huberty wrote.</p>\n<p>Wedbush’s Dan Ives echoed Huberty’s bullish call, citing strong iPhone 13 demand and the upcoming launch of augmented reality headsets.</p>\n<p>“This week our Apple store checks, supply chain data, and iPhone order delays all confirm our bullish view that currently demand is outstripping supply for iPhones 13 by roughly 10 million units globally,” Ives wrote in a research note Thursday.</p>\n<p>Ives estimated that Apple was on pace to sell more than 40 million iPhones during the holiday season, despite chip shortage and supply-chain headwinds. These headwinds are likely to be “nothing more than a speed bump” on the iPhone 12 and 13 cycle as consumers continue to upgrade their phones.</p>\n<p>Ives also foresees Apple launching AR headset “Apple Glasses” around the summer of 2022, which could add $20 per share to the company’s valuation.</p>\n<p>Other tailwinds include gaining a share of the PC market, strong cash returns, and future advances in augmented reality, payments, and talk of an upcoming expansion into vehicle manufacturing, Huberty added.</p>\n<p>“We also believe investors need to properly embed value from the optionality of upcoming new product launches,” she wrote.</p>\n<p>There are still some risks to the bullish case for Apple stock. Chief among them is that iPhone sales fail to materialize in 2022, as work-from-home demand peters off, Huberty outlined.</p>\n<p>Another risk could come with low growth in the services sector, potentially driven by court-imposed changes to the App Store payment model. Even that risk looked less likely as Apple notched another victory in its legal battle with Fortnite publisher Epic Games on Wednesday.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Nears $3 Trillion. Why It Could Still Be a Top Stock Pick for 2022.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Nears $3 Trillion. Why It Could Still Be a Top Stock Pick for 2022.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/apple-market-cap-3-trillion-top-stock-pick-51639073242?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple is a top stock pick for Morgan Stanley in 2022 as the tech giant nears a $3 trillion market capitalization and prepares to launch an augmented reality product.\n“The combination of a strong, ...</p>\n\n<a href=\"https://www.barrons.com/articles/apple-market-cap-3-trillion-top-stock-pick-51639073242?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-market-cap-3-trillion-top-stock-pick-51639073242?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169522079","content_text":"Apple is a top stock pick for Morgan Stanley in 2022 as the tech giant nears a $3 trillion market capitalization and prepares to launch an augmented reality product.\n“The combination of a strong, loyal customer base and the upcoming launch of AR/VR products positions AAPL for a re-rating in 2022,” analyst Katy Huberty wrote in a note Thursday. Huberty wrote that Apple was Morgan Stanley’s “favorite large cap (and overall Top Pick)” heading into 2022.\nHuberty’s call comes two days after she reiterated an Overweight rating on shares of Apple (ticker: AAPL) and raised her price target 21% to $200 from $164.\nApple shares were rising 0.2% to $175.47 on Thursday. The stock has risen about 32% this year, reaching a market capitalization of $2.87 trillion. Over the last month, it has jumped 19%, outperforming the Dow Jones Industrial Average’s 0.5% rise, the S&P 500’s 0.9% gain, and the Nasdaq Composite’s 0.04% advance.\nMorgan Stanley believes investors should value Apple as a consumer and technology platform rather than a cyclical hardware company, given that around a third of gross profits come from the company’s services segment. iPhone 13 demand will continue to drive growth in the short term, with new product launches in early 2022 continuing the trend, Huberty wrote.\nWedbush’s Dan Ives echoed Huberty’s bullish call, citing strong iPhone 13 demand and the upcoming launch of augmented reality headsets.\n“This week our Apple store checks, supply chain data, and iPhone order delays all confirm our bullish view that currently demand is outstripping supply for iPhones 13 by roughly 10 million units globally,” Ives wrote in a research note Thursday.\nIves estimated that Apple was on pace to sell more than 40 million iPhones during the holiday season, despite chip shortage and supply-chain headwinds. These headwinds are likely to be “nothing more than a speed bump” on the iPhone 12 and 13 cycle as consumers continue to upgrade their phones.\nIves also foresees Apple launching AR headset “Apple Glasses” around the summer of 2022, which could add $20 per share to the company’s valuation.\nOther tailwinds include gaining a share of the PC market, strong cash returns, and future advances in augmented reality, payments, and talk of an upcoming expansion into vehicle manufacturing, Huberty added.\n“We also believe investors need to properly embed value from the optionality of upcoming new product launches,” she wrote.\nThere are still some risks to the bullish case for Apple stock. Chief among them is that iPhone sales fail to materialize in 2022, as work-from-home demand peters off, Huberty outlined.\nAnother risk could come with low growth in the services sector, potentially driven by court-imposed changes to the App Store payment model. Even that risk looked less likely as Apple notched another victory in its legal battle with Fortnite publisher Epic Games on Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602148595,"gmtCreate":1639001454819,"gmtModify":1639001501437,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Apple apple Apple of my eye","listText":"Apple apple Apple of my eye","text":"Apple apple Apple of my eye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/602148595","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohu8.com/m/news/1161444269?lang=&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606721507,"gmtCreate":1638930341021,"gmtModify":1638930341283,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606721507","repostId":"1137636769","repostType":4,"repost":{"id":"1137636769","pubTimestamp":1638922009,"share":"https://www.laohu8.com/m/news/1137636769?lang=&edition=full","pubTime":"2021-12-08 08:06","market":"sg","language":"en","title":"Win Streak Expected To Continue For Singapore Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1137636769","media":"RTTNews","summary":"The Singapore stock market has finished higher in three straight sessions, collecting almost 45 poin","content":"<p>The Singapore stock market has finished higher in three straight sessions, collecting almost 45 points or 1.4 percent along the way. The Straits Times Index now sits just above the 3,130-point plateau and it figures to add to its winnings on Tuesday.</p>\n<p></p>\n<p>The global forecast for the Asian markets is upbeat on easing virus concerns, supported by tech and oil stocks. The European and U.S. markets were sharply higher and the Asian markets are tipped to open in similar fashion.</p>\n<p></p>\n<p>The STI finished modestly higher on Tuesday following gains from the financial shares and the industrial stocks.</p>\n<p></p>\n<p>For the day, the index gained 18.34 points or 0.59 percent to finish at 3,134.66 after trading between 3,120.44 and 3,138.41. Volume was 1.26 billion shares worth 1.13 billion Singapore dollars. There were 324 gainers and 159 decliners.</p>\n<p></p>\n<p>Among the actives, Ascendas REIT perked 0.34 percent, while City Developments accelerated 1.46 percent, Comfort DelGro sank 0.70 percent, Dairy Farm International was up 0.33 percent, DBS Group added 0.79 percent, Keppel Corp gathered 0.97 percent, Mapletree Commercial Trust rallied 0.99 percent, Oversea-Chinese Banking Corporation gained 0.62 percent, SATS jumped 1.29 percent, SembCorp Industries rose 0.50 percent, Singapore Airlines soared 2.25 percent, Singapore Exchange advanced 0.85 percent, Singapore Press Holdings increased 0.43 percent, Singapore Technologies Engineering added 0.27 percent, SingTel climbed 1.26 percent, Thai Beverage spiked 1.50 percent, United Overseas Bank collected 0.41 percent, Wilmar International improved 0.48 percent, Yangzijiang Shipbuilding surged 2.333 percent and Mapletree Logistics Trust, Genting Singapore and CapitaLand Integrated Commercial Trust were unchanged.</p>\n<p></p>\n<p>The lead from Wall Street is broadly positive as the major averages opened sharply higher on Tuesday and stayed that way throughout the session.</p>\n<p></p>\n<p>The Dow spiked 492.40 points or 1.40 percent to finish at 35,719.43, while the NASDAQ surged 461.76 points or 3.03 percent to close at 15,686.92 and the S&amp;P 500 jumped 95.08 points or 2.07 percent to end at 4,686.75.</p>\n<p></p>\n<p>Easing concerns about the impact of the Omicron variant of the coronavirus contributed to the continued strength on Wall Street. Indications the variant causes milder symptoms has helped offset worries the new strain could derail the global economic recovery.</p>\n<p></p>\n<p>Intel (INTC) fueled the rally as the semiconductor giant is jumped 3.1 percent to its best closing level in well over a month. The spike by Intel comes after the company announced its intention to take its self-driving car unit Mobileye public in the U.S. in mid-2022 via an initial public offering.</p>\n<p></p>\n<p>In U.S. economic news, the Commerce Department released a report showing the U.S. trade deficit narrowed significantly in the month of October amid a spike in the value of exports.</p>\n<p></p>\n<p>Crude oil prices rose sharply on Tuesday, lifting the most active futures contracts to their highest settlement in two weeks amid rising optimism about the outlook for energy demand. West Texas Intermediate Crude oil futures for January surged $2.56 or 3.7 percent at $72.05 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Win Streak Expected To Continue For Singapore Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWin Streak Expected To Continue For Singapore Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 08:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3247578/win-streak-expected-to-continue-for-singapore-stock-market.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has finished higher in three straight sessions, collecting almost 45 points or 1.4 percent along the way. The Straits Times Index now sits just above the 3,130-point plateau...</p>\n\n<a href=\"https://www.rttnews.com/3247578/win-streak-expected-to-continue-for-singapore-stock-market.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"C09.SI":"城市发展","A17U.SI":"凯德腾飞房产信托","STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3247578/win-streak-expected-to-continue-for-singapore-stock-market.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137636769","content_text":"The Singapore stock market has finished higher in three straight sessions, collecting almost 45 points or 1.4 percent along the way. The Straits Times Index now sits just above the 3,130-point plateau and it figures to add to its winnings on Tuesday.\n\nThe global forecast for the Asian markets is upbeat on easing virus concerns, supported by tech and oil stocks. The European and U.S. markets were sharply higher and the Asian markets are tipped to open in similar fashion.\n\nThe STI finished modestly higher on Tuesday following gains from the financial shares and the industrial stocks.\n\nFor the day, the index gained 18.34 points or 0.59 percent to finish at 3,134.66 after trading between 3,120.44 and 3,138.41. Volume was 1.26 billion shares worth 1.13 billion Singapore dollars. There were 324 gainers and 159 decliners.\n\nAmong the actives, Ascendas REIT perked 0.34 percent, while City Developments accelerated 1.46 percent, Comfort DelGro sank 0.70 percent, Dairy Farm International was up 0.33 percent, DBS Group added 0.79 percent, Keppel Corp gathered 0.97 percent, Mapletree Commercial Trust rallied 0.99 percent, Oversea-Chinese Banking Corporation gained 0.62 percent, SATS jumped 1.29 percent, SembCorp Industries rose 0.50 percent, Singapore Airlines soared 2.25 percent, Singapore Exchange advanced 0.85 percent, Singapore Press Holdings increased 0.43 percent, Singapore Technologies Engineering added 0.27 percent, SingTel climbed 1.26 percent, Thai Beverage spiked 1.50 percent, United Overseas Bank collected 0.41 percent, Wilmar International improved 0.48 percent, Yangzijiang Shipbuilding surged 2.333 percent and Mapletree Logistics Trust, Genting Singapore and CapitaLand Integrated Commercial Trust were unchanged.\n\nThe lead from Wall Street is broadly positive as the major averages opened sharply higher on Tuesday and stayed that way throughout the session.\n\nThe Dow spiked 492.40 points or 1.40 percent to finish at 35,719.43, while the NASDAQ surged 461.76 points or 3.03 percent to close at 15,686.92 and the S&P 500 jumped 95.08 points or 2.07 percent to end at 4,686.75.\n\nEasing concerns about the impact of the Omicron variant of the coronavirus contributed to the continued strength on Wall Street. Indications the variant causes milder symptoms has helped offset worries the new strain could derail the global economic recovery.\n\nIntel (INTC) fueled the rally as the semiconductor giant is jumped 3.1 percent to its best closing level in well over a month. The spike by Intel comes after the company announced its intention to take its self-driving car unit Mobileye public in the U.S. in mid-2022 via an initial public offering.\n\nIn U.S. economic news, the Commerce Department released a report showing the U.S. trade deficit narrowed significantly in the month of October amid a spike in the value of exports.\n\nCrude oil prices rose sharply on Tuesday, lifting the most active futures contracts to their highest settlement in two weeks amid rising optimism about the outlook for energy demand. West Texas Intermediate Crude oil futures for January surged $2.56 or 3.7 percent at $72.05 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606721643,"gmtCreate":1638930310811,"gmtModify":1638930597011,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope this will avert shortages of chips in future","listText":"Hope this will avert shortages of chips in future","text":"Hope this will avert shortages of chips in future","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606721643","repostId":"2189067658","repostType":4,"repost":{"id":"2189067658","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638928982,"share":"https://www.laohu8.com/m/news/2189067658?lang=&edition=full","pubTime":"2021-12-08 10:03","market":"us","language":"en","title":"Intel CEO aims to build chip plants with money raised from Mobileye IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2189067658","media":"Reuters","summary":"Dec 7  - Intel Corp will keep most of the money it raises next year when it sells a stake in its $Mobileye$ self-driving-vehicle components unit in a planned initial public offering, targeting some of those funds to build more Intel chip plants, Chief Executive Pat Gelsinger said on Tuesday.Intel shares were up 4.1% at midday Tuesday after surging as much as 8% during the session, as Wall Street cheered the chip giant's move to take Mobileye public. Gelsinger said the IPO will allow Mobileye to ","content":"<p>Dec 7 (Reuters) - Intel Corp will keep most of the money it raises next year when it sells a stake in its <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> self-driving-vehicle components unit in a planned initial public offering, targeting some of those funds to build more Intel chip plants, Chief Executive Pat Gelsinger said on Tuesday.</p>\n<p>Intel shares were up 4.1% at midday Tuesday after surging as much as 8% during the session, as Wall Street cheered the chip giant's move to take Mobileye public. Gelsinger said the IPO will allow Mobileye to grow more easily as global carmakers spend billions of dollars to accelerate their transition to electric and self-driving vehicles.</p>\n<p>\"This is the right time,\" he said on a conference call. \"This is a unique asset and we're going to make the right moves to fully realize that potential.\"</p>\n<p>Gelsinger said Intel will retain a majority stake in Mobileye and will also receive \"the majority of the proceeds\" from the IPO. He declined to specify the size of the stake that would be sold or a fundraising target, but said that \"certainly it will be helpful in our overall aggressive buildout of plants.\"</p>\n<p>Intel has said it plans to build two chip plants in Arizona, and add other plants in the United States and Europe at sites that have not been announced.</p>\n<p>A chip shortage has afflicted industries globally including the auto sector. U.S. President Joe Biden's administration wants Congress to approve $52 billion to expand U.S. semiconductor manufacturing.</p>\n<p>Before Tuesday's gains, Intel shares had barely budged this year, vastly underperforming a more than 40% rise in the Philadelphia SE Semiconductor index , as the chipmaker struggles to ramp up its technology as rivals have been making more energy-efficient microprocessors.</p>\n<p>Mobileye, an Israeli company that Intel bought for about $15 billion five years ago, could be valued at more than $50 billion during its U.S. IPO in mid-2022, a source previously told Reuters. Gelsinger said that value would be set closer to the IPO and he declined to say how much of Mobileye will be sold, repeating Intel would retain a majority stake.</p>\n<p>Mobileye has a rich roster of clients, including BMW, Audi, Volkswagen, Nissan, Honda and General Motors.</p>\n<p>Its technology has been deployed by automakers as they equip their cars with driver-assistance systems or experiment with self-driving technology in their shift toward electric vehicles.</p>\n<p>Intel expects Mobileye's revenue to grow over 40% this year.</p>\n<p>WestPark Capital analyst Ruben Roy liked the deal for the cash and greater strategic focus it could bring Intel. Roy said Mobileye should see compound annual growth of around 25% to 30% over the next several years.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel CEO aims to build chip plants with money raised from Mobileye IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel CEO aims to build chip plants with money raised from Mobileye IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-08 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 7 (Reuters) - Intel Corp will keep most of the money it raises next year when it sells a stake in its <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a> self-driving-vehicle components unit in a planned initial public offering, targeting some of those funds to build more Intel chip plants, Chief Executive Pat Gelsinger said on Tuesday.</p>\n<p>Intel shares were up 4.1% at midday Tuesday after surging as much as 8% during the session, as Wall Street cheered the chip giant's move to take Mobileye public. Gelsinger said the IPO will allow Mobileye to grow more easily as global carmakers spend billions of dollars to accelerate their transition to electric and self-driving vehicles.</p>\n<p>\"This is the right time,\" he said on a conference call. \"This is a unique asset and we're going to make the right moves to fully realize that potential.\"</p>\n<p>Gelsinger said Intel will retain a majority stake in Mobileye and will also receive \"the majority of the proceeds\" from the IPO. He declined to specify the size of the stake that would be sold or a fundraising target, but said that \"certainly it will be helpful in our overall aggressive buildout of plants.\"</p>\n<p>Intel has said it plans to build two chip plants in Arizona, and add other plants in the United States and Europe at sites that have not been announced.</p>\n<p>A chip shortage has afflicted industries globally including the auto sector. U.S. President Joe Biden's administration wants Congress to approve $52 billion to expand U.S. semiconductor manufacturing.</p>\n<p>Before Tuesday's gains, Intel shares had barely budged this year, vastly underperforming a more than 40% rise in the Philadelphia SE Semiconductor index , as the chipmaker struggles to ramp up its technology as rivals have been making more energy-efficient microprocessors.</p>\n<p>Mobileye, an Israeli company that Intel bought for about $15 billion five years ago, could be valued at more than $50 billion during its U.S. IPO in mid-2022, a source previously told Reuters. Gelsinger said that value would be set closer to the IPO and he declined to say how much of Mobileye will be sold, repeating Intel would retain a majority stake.</p>\n<p>Mobileye has a rich roster of clients, including BMW, Audi, Volkswagen, Nissan, Honda and General Motors.</p>\n<p>Its technology has been deployed by automakers as they equip their cars with driver-assistance systems or experiment with self-driving technology in their shift toward electric vehicles.</p>\n<p>Intel expects Mobileye's revenue to grow over 40% this year.</p>\n<p>WestPark Capital analyst Ruben Roy liked the deal for the cash and greater strategic focus it could bring Intel. Roy said Mobileye should see compound annual growth of around 25% to 30% over the next several years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4566":"资本集团","BK4099":"汽车制造商","BK4515":"5G概念","BK4535":"淡马锡持仓","BK4555":"新能源车","BK4550":"红杉资本持仓","BK4529":"IDC概念","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4534":"瑞士信贷持仓","BK4561":"索罗斯持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","INTC":"英特尔","BK4512":"苹果概念","BK4141":"半导体产品"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189067658","content_text":"Dec 7 (Reuters) - Intel Corp will keep most of the money it raises next year when it sells a stake in its Mobileye self-driving-vehicle components unit in a planned initial public offering, targeting some of those funds to build more Intel chip plants, Chief Executive Pat Gelsinger said on Tuesday.\nIntel shares were up 4.1% at midday Tuesday after surging as much as 8% during the session, as Wall Street cheered the chip giant's move to take Mobileye public. Gelsinger said the IPO will allow Mobileye to grow more easily as global carmakers spend billions of dollars to accelerate their transition to electric and self-driving vehicles.\n\"This is the right time,\" he said on a conference call. \"This is a unique asset and we're going to make the right moves to fully realize that potential.\"\nGelsinger said Intel will retain a majority stake in Mobileye and will also receive \"the majority of the proceeds\" from the IPO. He declined to specify the size of the stake that would be sold or a fundraising target, but said that \"certainly it will be helpful in our overall aggressive buildout of plants.\"\nIntel has said it plans to build two chip plants in Arizona, and add other plants in the United States and Europe at sites that have not been announced.\nA chip shortage has afflicted industries globally including the auto sector. U.S. President Joe Biden's administration wants Congress to approve $52 billion to expand U.S. semiconductor manufacturing.\nBefore Tuesday's gains, Intel shares had barely budged this year, vastly underperforming a more than 40% rise in the Philadelphia SE Semiconductor index , as the chipmaker struggles to ramp up its technology as rivals have been making more energy-efficient microprocessors.\nMobileye, an Israeli company that Intel bought for about $15 billion five years ago, could be valued at more than $50 billion during its U.S. IPO in mid-2022, a source previously told Reuters. Gelsinger said that value would be set closer to the IPO and he declined to say how much of Mobileye will be sold, repeating Intel would retain a majority stake.\nMobileye has a rich roster of clients, including BMW, Audi, Volkswagen, Nissan, Honda and General Motors.\nIts technology has been deployed by automakers as they equip their cars with driver-assistance systems or experiment with self-driving technology in their shift toward electric vehicles.\nIntel expects Mobileye's revenue to grow over 40% this year.\nWestPark Capital analyst Ruben Roy liked the deal for the cash and greater strategic focus it could bring Intel. Roy said Mobileye should see compound annual growth of around 25% to 30% over the next several years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606723728,"gmtCreate":1638930265999,"gmtModify":1638930709393,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"All talk to spook people and cause uneasiness. One minute good the next minute no good must have cocktails of vaccination… people are dead tired and need a break.","listText":"All talk to spook people and cause uneasiness. One minute good the next minute no good must have cocktails of vaccination… people are dead tired and need a break.","text":"All talk to spook people and cause uneasiness. One minute good the next minute no good must have cocktails of vaccination… people are dead tired and need a break.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606723728","repostId":"1104596596","repostType":4,"repost":{"id":"1104596596","pubTimestamp":1638928083,"share":"https://www.laohu8.com/m/news/1104596596?lang=&edition=full","pubTime":"2021-12-08 09:48","market":"us","language":"en","title":"Study suggests Pfizer COVID-19 vaccine may only partially protect against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1104596596","media":"finance.yahoo","summary":"Dec 7 (Reuters) - The Omicron variant of the coronavirus can partially evade the protection from two","content":"<p>Dec 7 (Reuters) - The Omicron variant of the coronavirus can partially evade the protection from two doses of Pfizer Inc and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on Tuesday.</p>\n<p>Still, the study showed that blood from people who had received two doses of the vaccine and had a prior infection were mostly able to neutralize the variant, suggesting that booster doses of the vaccine could help to fend off infection.</p>\n<p>Alex Sigal, a professor at the Africa Health Research Institute, said on Twitter there was \"a very large drop\" in neutralization of the Omicron variant relative to an earlier strain of COVID-19.</p>\n<p>The lab tested blood from 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer reviewed.</p>\n<p>Blood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.</p>\n<p>\"These results are better than I expected. The more antibodies you got, the more chance you'll be protected from Omicron,\" Sigal said on Twitter.</p>\n<p>He said the lab had not tested the variant against blood from people who had received a booster dose, because they are not available in South Africa yet.</p>\n<p>According to the manuscript, the lab observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.</p>\n<p>Sigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.</p>\n<p>While neutralizing antibodies are an indicator of the body's immune response, scientists believe other kinds of cells such as B-cells and T-cells also are stimulated by the vaccines and help protect against the effects of the coronavirus.</p>\n<p>The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.</p>\n<p>The World Health Organization classified it on Nov. 26 as a \"variant of concern,\" but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.</p>\n<p>There is not significant data yet on how vaccines from Moderna, Johnson &amp; Johnson and other drugmakers hold up against the new variant. All the manufacturers, including Pfizer and BioNTech, are expected to release their own data within weeks.</p>\n<p>BioNTech CEO Ugur Sahin told NBC News on Tuesday that the drugmaker has data coming on Wednesday or Thursday related to the new variant.</p>\n<p>Top U.S. infectious disease expert Dr. Anthony Fauci said on Tuesday that preliminary evidence indicates that the Omicron variant of the coronavirus likely has a higher degree of transmissibility but is less severe.</p>\n<p>He said the United States was doing its own tests to determine the protectiveness of the current vaccines against the variant and expects results sometime next week.</p>\n<p>Umer Raffat, an analyst for Evercore ISI, cautioned against reading too much into a single study, noting there has been significant variability in measuring declines in antibody levels in previous lab studies.</p>\n<p>\"Let’s wait for additional studies to draw a mosaic,\" he said.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Study suggests Pfizer COVID-19 vaccine may only partially protect against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStudy suggests Pfizer COVID-19 vaccine may only partially protect against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 09:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-pfizer-covid-19-vaccine-210033404.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 7 (Reuters) - The Omicron variant of the coronavirus can partially evade the protection from two doses of Pfizer Inc and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-pfizer-covid-19-vaccine-210033404.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-pfizer-covid-19-vaccine-210033404.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104596596","content_text":"Dec 7 (Reuters) - The Omicron variant of the coronavirus can partially evade the protection from two doses of Pfizer Inc and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on Tuesday.\nStill, the study showed that blood from people who had received two doses of the vaccine and had a prior infection were mostly able to neutralize the variant, suggesting that booster doses of the vaccine could help to fend off infection.\nAlex Sigal, a professor at the Africa Health Research Institute, said on Twitter there was \"a very large drop\" in neutralization of the Omicron variant relative to an earlier strain of COVID-19.\nThe lab tested blood from 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer reviewed.\nBlood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.\n\"These results are better than I expected. The more antibodies you got, the more chance you'll be protected from Omicron,\" Sigal said on Twitter.\nHe said the lab had not tested the variant against blood from people who had received a booster dose, because they are not available in South Africa yet.\nAccording to the manuscript, the lab observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.\nSigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.\nWhile neutralizing antibodies are an indicator of the body's immune response, scientists believe other kinds of cells such as B-cells and T-cells also are stimulated by the vaccines and help protect against the effects of the coronavirus.\nThe Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.\nThe World Health Organization classified it on Nov. 26 as a \"variant of concern,\" but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.\nThere is not significant data yet on how vaccines from Moderna, Johnson & Johnson and other drugmakers hold up against the new variant. All the manufacturers, including Pfizer and BioNTech, are expected to release their own data within weeks.\nBioNTech CEO Ugur Sahin told NBC News on Tuesday that the drugmaker has data coming on Wednesday or Thursday related to the new variant.\nTop U.S. infectious disease expert Dr. Anthony Fauci said on Tuesday that preliminary evidence indicates that the Omicron variant of the coronavirus likely has a higher degree of transmissibility but is less severe.\nHe said the United States was doing its own tests to determine the protectiveness of the current vaccines against the variant and expects results sometime next week.\nUmer Raffat, an analyst for Evercore ISI, cautioned against reading too much into a single study, noting there has been significant variability in measuring declines in antibody levels in previous lab studies.\n\"Let’s wait for additional studies to draw a mosaic,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606957968,"gmtCreate":1638828518357,"gmtModify":1638828743462,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope all is well","listText":"Hope all is well","text":"Hope all is well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606957968","repostId":"1172118771","repostType":4,"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606954592,"gmtCreate":1638828472858,"gmtModify":1638842190312,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"People are still confused on the potency of the omicron virus. So mix feeling","listText":"People are still confused on the potency of the omicron virus. So mix feeling","text":"People are still confused on the potency of the omicron virus. So mix feeling","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606954592","repostId":"1172118771","repostType":4,"repost":{"id":"1172118771","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638803122,"share":"https://www.laohu8.com/m/news/1172118771?lang=&edition=full","pubTime":"2021-12-06 23:05","market":"us","language":"en","title":"Vaccine stocks mixed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1172118771","media":"Tiger Newspress","summary":"Vaccine stocks mixed in morning trading.Moderna and BioNTech SE plunged more than 12% while Johnson ","content":"<p>Vaccine&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.Moderna and BioNTech SE plunged more than 12% while Johnson &amp; Johnson and&nbsp;AstraZeneca&nbsp;rose&nbsp;about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/a026a8b3f73899e06c8e4913061f6618\" tg-width=\"410\" tg-height=\"722\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks mixed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks mixed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.Moderna and BioNTech SE plunged more than 12% while Johnson &amp; Johnson and&nbsp;AstraZeneca&nbsp;rose&nbsp;about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/a026a8b3f73899e06c8e4913061f6618\" tg-width=\"410\" tg-height=\"722\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","SNY":"赛诺菲安万特","GSK":"葛兰素史克","MRK":"默沙东","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","LLY":"礼来","PFE":"辉瑞","GILD":"吉利德科学","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172118771","content_text":"Vaccine stocks mixed in morning trading.Moderna and BioNTech SE plunged more than 12% while Johnson & Johnson and AstraZeneca rose about 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606034327,"gmtCreate":1638800487278,"gmtModify":1638800487539,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Fly high high&nbsp;","listText":"Fly high high&nbsp;","text":"Fly high high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/606034327","repostId":"1125140621","repostType":4,"repost":{"id":"1125140621","pubTimestamp":1638799944,"share":"https://www.laohu8.com/m/news/1125140621?lang=&edition=full","pubTime":"2021-12-06 22:12","market":"us","language":"en","title":"Will Apple Stock Fly or Fall in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1125140621","media":"Motley Fool","summary":"Supply chain challenges and weak demand could derail the iPhone maker.","content":"<p>Shares of&nbsp;<b>Apple</b>&nbsp;have recovered nicely in 2021 after a shaky start to the year, gaining more than 23%. What's impressive is that Apple has staged a comeback despite&nbsp;supply chain challenges&nbsp;that hurt its sales in the fourth quarter of fiscal 2021 (which ended on Sept. 25). In addition, investors have shown their faith in the tech giant even with weaker-than-expected guidance for the quarter that ends in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/01f45160862cc6cb5e3ed7b3185ae9a9\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>AAPL data by YCharts.</span></p>\n<p>As the chart above shows, Apple stock has gained momentum since the beginning of October. That's not surprising as the&nbsp;launch of the iPhone 13&nbsp;gave investors a reason to cheer, with the device witnessing robust demand that outpaced supply. The company hasn't been able to make enough iPhones to meet the higher-than-expected demand as component shortages and coronavirus-driven shutdowns crippled production.</p>\n<p>In an ideal world, this should lead to strong iPhone shipments in 2022 when the supply chain improves, boosting Apple's top and bottom lines and its stock price in the process. But that may not be the case, causing the stock to lose momentum early in the new year. Let's see why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9f332fa65e3d67539a23dd91573637d\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p><b>Why Apple stock might fall next year</b></p>\n<p>The iPhone is Apple's most important product. It produced nearly $192 billion in revenue for the company in fiscal 2021, which was just over 52% of its total revenue of $365.8 billion. Now, there are rumors that Apple may be losing customers due to its inability to make enough iPhones to satisfy demand.</p>\n<p>According to a Bloomberg report, the company has reportedly&nbsp;told its component suppliers that the demand for iPhone 13 models has weakened as potential consumers aren't interested anymore in buying the device due to lack of availability. A survey carried out in Japan indicates that the number of existing iPhone owners interested in upgrading to the latest device is lower than last year when more people were interested in upgrading to the iPhone 12.</p>\n<p>One of the reasons that may be the case is because of the long waiting times for the iPhone 13 Pro models, which are in stronger demand than the standard models. Third-party reports showed that the waiting time for the iPhone 13 Pro and the Pro Max ranged between&nbsp;16 days and 23 days on Nov. 28. It is worth noting that Apple had&nbsp;reportedly reduced&nbsp;its 2021 iPhone 13 production target by 10 million units due to component shortages, which explains why its devices are still showing extensive waiting times.</p>\n<p>The problem is that iPhone 13 delays are expected to last until February 2022, as reported by DigiTimes last month. These long waiting times and delays are reportedly causing customers to put off their iPhone 13 purchases. This isn't surprising, as the iPhone 13 will be nearly half a year old by the time it will be readily available for purchase in February next year.</p>\n<p>This could lead customers to drop the idea of purchasing the iPhone 13 and instead go for the 2022 models. As a result, iPhone revenue could take a hit in the near term and weigh on the company's financial performance and stock price in 2022.</p>\n<p><b>The stock could fly higher in the long run</b></p>\n<p>Savvy investors, however, shouldn't worry about the potential short-term challenges Apple faces. Even if iPhone sales aren't as great as expected in the early part of 2022 due to problems out of the tech titan's control, one shouldn't forget the massive upgrade cycle that's driving Apple's growth.</p>\n<p>According to IDC, Apple shipped 50.4 million iPhones in the third quarter of 2021, a jump of nearly 21% over the year-ago period. The company delivered this impressive growth during a quarter when the overall smartphone market contracted 6.7% year over year, with its biggest rivals&nbsp;<b>Samsung</b>&nbsp;and&nbsp;<b>Xiaomi</b>&nbsp;witnessing a contraction in their shipments.</p>\n<p>What's more, Apple is&nbsp;enjoying a nice bump&nbsp;in the average selling price of each iPhone. Sales might be hamstrung by component shortages over the next few months, but it cannot be denied that the company is enjoying a mix of volume and price growth thanks to the adoption of 5G smartphones.</p>\n<p>More importantly, there were more than a billion iPhone users at the beginning of 2021. Wedbush analyst Dan Ives pointed out in October that 25% of Apple's installed base of users haven't upgraded their iPhones in the past three and a half years, which means that there are at least 250 million users in an upgrade window who could buy the iPhone 13.</p>\n<p>Additionally, the number of iPhone users&nbsp;without a 5G device&nbsp;is even higher since the first 5G iPhone went on sale&nbsp;just over a year ago. All of this indicates that investors shouldn't miss the forest for the trees as the iPhone juggernaut can continue rolling in the long run and the supply chain constraints would probably be just a bump in the road.</p>\n<p>As such, Apple stock can eventually regain its mojo once it gets the production challenges out of the way in 2022 and ships more iPhones to customers. And this is just one of the reasons this&nbsp;tech stock&nbsp;could fly higher next year as it is&nbsp;working on more products&nbsp;that could accelerate its growth in 2022 and beyond. That's why it might be a good idea to buy the stock in case of a dip as the near-term challenges could eventually make way for long-term gains.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Apple Stock Fly or Fall in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Apple Stock Fly or Fall in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/06/will-apple-stock-fly-or-fall-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Apple have recovered nicely in 2021 after a shaky start to the year, gaining more than 23%. What's impressive is that Apple has staged a comeback despite supply chain challenges that hurt ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/06/will-apple-stock-fly-or-fall-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2021/12/06/will-apple-stock-fly-or-fall-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125140621","content_text":"Shares of Apple have recovered nicely in 2021 after a shaky start to the year, gaining more than 23%. What's impressive is that Apple has staged a comeback despite supply chain challenges that hurt its sales in the fourth quarter of fiscal 2021 (which ended on Sept. 25). In addition, investors have shown their faith in the tech giant even with weaker-than-expected guidance for the quarter that ends in December.\nAAPL data by YCharts.\nAs the chart above shows, Apple stock has gained momentum since the beginning of October. That's not surprising as the launch of the iPhone 13 gave investors a reason to cheer, with the device witnessing robust demand that outpaced supply. The company hasn't been able to make enough iPhones to meet the higher-than-expected demand as component shortages and coronavirus-driven shutdowns crippled production.\nIn an ideal world, this should lead to strong iPhone shipments in 2022 when the supply chain improves, boosting Apple's top and bottom lines and its stock price in the process. But that may not be the case, causing the stock to lose momentum early in the new year. Let's see why.\nImage Source: Getty Images.\nWhy Apple stock might fall next year\nThe iPhone is Apple's most important product. It produced nearly $192 billion in revenue for the company in fiscal 2021, which was just over 52% of its total revenue of $365.8 billion. Now, there are rumors that Apple may be losing customers due to its inability to make enough iPhones to satisfy demand.\nAccording to a Bloomberg report, the company has reportedly told its component suppliers that the demand for iPhone 13 models has weakened as potential consumers aren't interested anymore in buying the device due to lack of availability. A survey carried out in Japan indicates that the number of existing iPhone owners interested in upgrading to the latest device is lower than last year when more people were interested in upgrading to the iPhone 12.\nOne of the reasons that may be the case is because of the long waiting times for the iPhone 13 Pro models, which are in stronger demand than the standard models. Third-party reports showed that the waiting time for the iPhone 13 Pro and the Pro Max ranged between 16 days and 23 days on Nov. 28. It is worth noting that Apple had reportedly reduced its 2021 iPhone 13 production target by 10 million units due to component shortages, which explains why its devices are still showing extensive waiting times.\nThe problem is that iPhone 13 delays are expected to last until February 2022, as reported by DigiTimes last month. These long waiting times and delays are reportedly causing customers to put off their iPhone 13 purchases. This isn't surprising, as the iPhone 13 will be nearly half a year old by the time it will be readily available for purchase in February next year.\nThis could lead customers to drop the idea of purchasing the iPhone 13 and instead go for the 2022 models. As a result, iPhone revenue could take a hit in the near term and weigh on the company's financial performance and stock price in 2022.\nThe stock could fly higher in the long run\nSavvy investors, however, shouldn't worry about the potential short-term challenges Apple faces. Even if iPhone sales aren't as great as expected in the early part of 2022 due to problems out of the tech titan's control, one shouldn't forget the massive upgrade cycle that's driving Apple's growth.\nAccording to IDC, Apple shipped 50.4 million iPhones in the third quarter of 2021, a jump of nearly 21% over the year-ago period. The company delivered this impressive growth during a quarter when the overall smartphone market contracted 6.7% year over year, with its biggest rivals Samsung and Xiaomi witnessing a contraction in their shipments.\nWhat's more, Apple is enjoying a nice bump in the average selling price of each iPhone. Sales might be hamstrung by component shortages over the next few months, but it cannot be denied that the company is enjoying a mix of volume and price growth thanks to the adoption of 5G smartphones.\nMore importantly, there were more than a billion iPhone users at the beginning of 2021. Wedbush analyst Dan Ives pointed out in October that 25% of Apple's installed base of users haven't upgraded their iPhones in the past three and a half years, which means that there are at least 250 million users in an upgrade window who could buy the iPhone 13.\nAdditionally, the number of iPhone users without a 5G device is even higher since the first 5G iPhone went on sale just over a year ago. All of this indicates that investors shouldn't miss the forest for the trees as the iPhone juggernaut can continue rolling in the long run and the supply chain constraints would probably be just a bump in the road.\nAs such, Apple stock can eventually regain its mojo once it gets the production challenges out of the way in 2022 and ships more iPhones to customers. And this is just one of the reasons this tech stock could fly higher next year as it is working on more products that could accelerate its growth in 2022 and beyond. That's why it might be a good idea to buy the stock in case of a dip as the near-term challenges could eventually make way for long-term gains.","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608135807,"gmtCreate":1638663320718,"gmtModify":1638663320886,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Roller coaster for the daring soul who have extra cash.","listText":"Roller coaster for the daring soul who have extra cash.","text":"Roller coaster for the daring soul who have extra cash.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608135807","repostId":"1140678193","repostType":4,"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":690856288,"gmtCreate":1639657592879,"gmtModify":1639657593231,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good if we had brought the share earlier&nbsp;","listText":"Good if we had brought the share earlier&nbsp;","text":"Good if we had brought the share earlier","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690856288","repostId":"1122700546","repostType":4,"repost":{"id":"1122700546","pubTimestamp":1639656448,"share":"https://www.laohu8.com/m/news/1122700546?lang=&edition=full","pubTime":"2021-12-16 20:07","market":"us","language":"en","title":"Shopify rallies after Evercore ISI calls out +25% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1122700546","media":"Seeking Alpha","summary":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.","content":"<ul>\n <li>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.</li>\n <li>Analyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.</li>\n <li>Shares of SHOP are&nbsp;up 3.08%&nbsp;in premarket action to $1,410.26.</li>\n <li>Evercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the&nbsp;average Wall Street PT of $1,698.19.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shopify rallies after Evercore ISI calls out +25% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShopify rallies after Evercore ISI calls out +25% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/...</p>\n\n<a href=\"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SHOP":"Shopify Inc"},"source_url":"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122700546","content_text":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.\nShares of SHOP are up 3.08% in premarket action to $1,410.26.\nEvercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the average Wall Street PT of $1,698.19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602148595,"gmtCreate":1639001454819,"gmtModify":1639001501437,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Apple apple Apple of my eye","listText":"Apple apple Apple of my eye","text":"Apple apple Apple of my eye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/602148595","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohu8.com/m/news/1161444269?lang=&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857502099,"gmtCreate":1635545082635,"gmtModify":1635545082771,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Help mankind to end this pandemic&nbsp;","listText":"Help mankind to end this pandemic&nbsp;","text":"Help mankind to end this pandemic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/857502099","repostId":"2179249313","repostType":4,"repost":{"id":"2179249313","pubTimestamp":1635517740,"share":"https://www.laohu8.com/m/news/2179249313?lang=&edition=full","pubTime":"2021-10-29 22:29","market":"us","language":"en","title":"Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2179249313","media":"StreetInsider","summary":"Q2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.","content":"<p><i>Q2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.5 million doses for delivery in the second quarter of 2022</i></p>\n<p><i>Per the original APA, COVAX Facility retains options for up to 233 million additional doses in 2022</i></p>\n<p><i>Doses provided at lowest tiered price, in keeping with Moderna’s global access principles commitment</i></p>\n<p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with Gavi, the Vaccine Alliance to supply up 116.5 million doses of Moderna’s COVID-19 vaccine to be delivered in the second quarter of 2022. The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses of Moderna’s COVID-19 vaccine that was communicated earlier this year. As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi continues to retain the option to procure 233 million additional doses in 2022 for a potential total of 500 million doses between 2021 and 2022 under the agreement. All doses are offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.</p>\n<p>This agreement covers the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.</p>\n<p>“I am grateful to our partners at Gavi and COVAX for their work and collaboration to reach this agreement. This is another important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine. We have recently offered to COVAX to access more vaccines for Q2 and Q3 2022.”</p>\n<p><b>About Moderna</b></p>\n<p>In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the earliest and most-effective vaccines against the COVID-19 pandemic.</p>\n<p>Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by <i>Science</i> for the past seven years. To learn more, visit www.modernatx.com.</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine against COVID-19 (mRNA-1273); sales of mRNA-1273 to the COVAX Facility and the timing for delivery of that supply; and the potential for the exercise of options by the COVAX Facility for further purchases of mRNA-1273. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-29 22:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19128548><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Q2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.5 million doses for delivery in the second quarter of 2022\nPer the original APA, COVAX Facility ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19128548\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19128548","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179249313","content_text":"Q2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.5 million doses for delivery in the second quarter of 2022\nPer the original APA, COVAX Facility retains options for up to 233 million additional doses in 2022\nDoses provided at lowest tiered price, in keeping with Moderna’s global access principles commitment\nCAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with Gavi, the Vaccine Alliance to supply up 116.5 million doses of Moderna’s COVID-19 vaccine to be delivered in the second quarter of 2022. The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses of Moderna’s COVID-19 vaccine that was communicated earlier this year. As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi continues to retain the option to procure 233 million additional doses in 2022 for a potential total of 500 million doses between 2021 and 2022 under the agreement. All doses are offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.\nThis agreement covers the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.\n“I am grateful to our partners at Gavi and COVAX for their work and collaboration to reach this agreement. This is another important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine. We have recently offered to COVAX to access more vaccines for Q2 and Q3 2022.”\nAbout Moderna\nIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.\nModerna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine against COVID-19 (mRNA-1273); sales of mRNA-1273 to the COVAX Facility and the timing for delivery of that supply; and the potential for the exercise of options by the COVAX Facility for further purchases of mRNA-1273. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.","news_type":1},"isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827119869,"gmtCreate":1634432210130,"gmtModify":1634432210618,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/827119869","repostId":"1188641122","repostType":4,"repost":{"id":"1188641122","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634305460,"share":"https://www.laohu8.com/m/news/1188641122?lang=&edition=full","pubTime":"2021-10-15 21:44","market":"us","language":"en","title":"EV stocks rose in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1188641122","media":"Tiger Newspress","summary":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.\n\nTes","content":"<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/718cbd03e21f15e45c2574be4e4017b5\" tg-width=\"401\" tg-height=\"242\" referrerpolicy=\"no-referrer\"></p>\n<p>Tesla&nbsp;edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker&nbsp;to $950 from $850.</p>\n<p>Analyst&nbsp;Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.</p>\n<p>Following further analysis of third-quarter data and various sources of information on the&nbsp;soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.</p>\n<p>In addition,&nbsp;Houchois said&nbsp;sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"</p>\n<p>Chinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.</p>\n<p>XPeng&nbsp;published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.</p>\n<p>Solid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-15 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/718cbd03e21f15e45c2574be4e4017b5\" tg-width=\"401\" tg-height=\"242\" referrerpolicy=\"no-referrer\"></p>\n<p>Tesla&nbsp;edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker&nbsp;to $950 from $850.</p>\n<p>Analyst&nbsp;Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.</p>\n<p>Following further analysis of third-quarter data and various sources of information on the&nbsp;soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.</p>\n<p>In addition,&nbsp;Houchois said&nbsp;sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"</p>\n<p>Chinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.</p>\n<p>XPeng&nbsp;published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.</p>\n<p>Solid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188641122","content_text":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.\n\nTesla edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker to $950 from $850.\nAnalyst Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.\nFollowing further analysis of third-quarter data and various sources of information on the soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.\nIn addition, Houchois said sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"\nChinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.\nXPeng published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.\nSolid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.","news_type":1},"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699820204,"gmtCreate":1639783010615,"gmtModify":1639783010984,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good lah. Help the people","listText":"Good lah. Help the people","text":"Good lah. Help the people","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699820204","repostId":"1155244596","repostType":4,"repost":{"id":"1155244596","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752003,"share":"https://www.laohu8.com/m/news/1155244596?lang=&edition=full","pubTime":"2021-12-17 22:40","market":"us","language":"en","title":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list","url":"https://stock-news.laohu8.com/highlight/detail?id=1155244596","media":"Tiger Newspress","summary":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emerg","content":"<p>Novavax continued to jump nearly&nbsp;5% in morning trading as its vaccine had been included on the&nbsp;emergency use list.<img src=\"https://static.tigerbbs.com/6e0b5588f7377a98c70179cdc8612b3f\" tg-width=\"765\" tg-height=\"561\" width=\"100%\" height=\"auto\">The World Health Organization has included&nbsp;its&nbsp;vaccine NVX-CoV2373 on the emergency use list,and its&nbsp;original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax continued to jump nearly&nbsp;5% in morning trading as its vaccine had been included on the&nbsp;emergency use list.<img src=\"https://static.tigerbbs.com/6e0b5588f7377a98c70179cdc8612b3f\" tg-width=\"765\" tg-height=\"561\" width=\"100%\" height=\"auto\">The World Health Organization has included&nbsp;its&nbsp;vaccine NVX-CoV2373 on the emergency use list,and its&nbsp;original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155244596","content_text":"Novavax continued to jump nearly 5% in morning trading as its vaccine had been included on the emergency use list.The World Health Organization has included its vaccine NVX-CoV2373 on the emergency use list,and its original drug called nuvaxovidtm is currently undergoing evaluation by the European Medicines Agency.","news_type":1},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601280017,"gmtCreate":1638534699664,"gmtModify":1638534699876,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Huat already….keep huating","listText":"Huat already….keep huating","text":"Huat already….keep huating","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601280017","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohu8.com/m/news/1144924535?lang=&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p>\n<p>Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875356180,"gmtCreate":1637618513875,"gmtModify":1637618514078,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"The apple of our eye","listText":"The apple of our eye","text":"The apple of our eye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/875356180","repostId":"1158210333","repostType":4,"repost":{"id":"1158210333","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637592769,"share":"https://www.laohu8.com/m/news/1158210333?lang=&edition=full","pubTime":"2021-11-22 22:52","market":"us","language":"en","title":"Apple shares rose nearly 2% in early trading and hit a record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1158210333","media":"Tiger Newspress","summary":"Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;hit&nbsp;a&nbsp;record&nbsp;high.","content":"<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;hit&nbsp;a&nbsp;record&nbsp;high.<img src=\"https://static.tigerbbs.com/dfbbc5a5ac25a614e99178ea5fd19166\" tg-width=\"883\" tg-height=\"601\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% in early trading and hit a record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% in early trading and hit a record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-22 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;hit&nbsp;a&nbsp;record&nbsp;high.<img src=\"https://static.tigerbbs.com/dfbbc5a5ac25a614e99178ea5fd19166\" tg-width=\"883\" tg-height=\"601\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158210333","content_text":"Apple shares rose nearly 2% in early trading and hit a record high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876707070,"gmtCreate":1637359856665,"gmtModify":1637359857144,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Electric cars which are using sustainable energy will be the in thing now","listText":"Electric cars which are using sustainable energy will be the in thing now","text":"Electric cars which are using sustainable energy will be the in thing now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876707070","repostId":"1190357165","repostType":4,"repost":{"id":"1190357165","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637335635,"share":"https://www.laohu8.com/m/news/1190357165?lang=&edition=full","pubTime":"2021-11-19 23:27","market":"us","language":"en","title":"EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6% ","url":"https://stock-news.laohu8.com/highlight/detail?id=1190357165","media":"Tiger Newspress","summary":"EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6%.Apple is back front and center of the talk in the electric vehicle sector with Bloomberg reporting the tech giant is targeting a launch of a self-driving car in four years. Apple's progress in developing a chip made up primarily of neural processors that can handle the artificial intelligence needed for autonomous driving is the driving force in pushing the Apple Car project ahead again.","content":"<p>EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6%.<img src=\"https://static.tigerbbs.com/bf30bb80e11766be1ebdd4f81a55f6bd\" tg-width=\"277\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Apple&nbsp;is back front and center of the talk in the electric vehicle sector with Bloomberg reporting the tech giant is targeting a launch of a self-driving car in four years. Apple's&nbsp;progress in developing a chip made up primarily of neural processors that can handle the artificial intelligence needed for autonomous driving is the driving force in pushing the Apple Car project ahead again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6% </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6% \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 23:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6%.<img src=\"https://static.tigerbbs.com/bf30bb80e11766be1ebdd4f81a55f6bd\" tg-width=\"277\" tg-height=\"244\" referrerpolicy=\"no-referrer\">Apple&nbsp;is back front and center of the talk in the electric vehicle sector with Bloomberg reporting the tech giant is targeting a launch of a self-driving car in four years. Apple's&nbsp;progress in developing a chip made up primarily of neural processors that can handle the artificial intelligence needed for autonomous driving is the driving force in pushing the Apple Car project ahead again.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190357165","content_text":"EV stocks bounced in morning trading, with Lucid jumping nearly 12% and Rivian rising over 6%.Apple is back front and center of the talk in the electric vehicle sector with Bloomberg reporting the tech giant is targeting a launch of a self-driving car in four years. Apple's progress in developing a chip made up primarily of neural processors that can handle the artificial intelligence needed for autonomous driving is the driving force in pushing the Apple Car project ahead again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873055754,"gmtCreate":1636809936281,"gmtModify":1636809936421,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Woaw good news for stockholder","listText":"Woaw good news for stockholder","text":"Woaw good news for stockholder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873055754","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848701020,"gmtCreate":1636025535869,"gmtModify":1636025536302,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Already make so much. Relax lah","listText":"Already make so much. Relax lah","text":"Already make so much. Relax lah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848701020","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohu8.com/m/news/1101079537?lang=&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1},"isVote":1,"tweetType":1,"viewCount":23,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829717985,"gmtCreate":1633557620258,"gmtModify":1633557620785,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Will it dip further before we buy","listText":"Will it dip further before we buy","text":"Will it dip further before we buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/829717985","repostId":"2173791088","repostType":4,"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864009025,"gmtCreate":1633038143901,"gmtModify":1633038144334,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"If we have to be vaccinated yearly, they will definitely be benefited.","listText":"If we have to be vaccinated yearly, they will definitely be benefited.","text":"If we have to be vaccinated yearly, they will definitely be benefited.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/864009025","repostId":"1197813728","repostType":4,"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876375630,"gmtCreate":1637278364275,"gmtModify":1637278364415,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good news for people who have the stock","listText":"Good news for people who have the stock","text":"Good news for people who have the stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/876375630","repostId":"1173100100","repostType":4,"repost":{"id":"1173100100","pubTimestamp":1637249733,"share":"https://www.laohu8.com/m/news/1173100100?lang=&edition=full","pubTime":"2021-11-18 23:35","market":"us","language":"en","title":"Apple Stock: Record Level Is Around the Corner","url":"https://stock-news.laohu8.com/highlight/detail?id=1173100100","media":"TheStreet","summary":"Apple stock had a strong day of performance on November 17, and is now $3 per share away from the pe","content":"<p>Apple stock had a strong day of performance on November 17, and is now $3 per share away from the peak. Here is what investors should keep in mind.</p>\n<p>On Wednesday, November 17, Apple stock&nbsp;climbed nearly 2% to end the trading session valued at about $154 per share, backed by the heaviest trading volume of the month so far. This is the highest that the stock has reached since early September 2021, when the current all-time high of $156.46 was set.</p>\n<p>Below are a few factors that may be driving bullishness, and what AAPL investors should expect of the stock next.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/093d1adcfe3c452520b68115237e874d\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>The iPhone</span></p>\n<p><b>Why so bullish?</b></p>\n<p>Apple stock's 1.7% climb on Wednesday was much better than the return of the S&amp;P 500, at a modest loss of 0.3%. Interestingly enough, despite AAPL's strong performance, it was not easy to pinpoint one single cause for the outsized single-day gain.</p>\n<p>Maybe the company's&nbsp;announcement&nbsp;of the Self Service Repair program, to be launched in 2022, had something to do with it. By effectively outsourcing simple services to users, Apple might be able to simplify its service and cost structure.</p>\n<p>However, I doubt that this piece of news alone was responsible for creating $40 billion in market value. Instead, I bet that bullishness has been merely a reflection of recent skepticism over the company's ability to perform in the near term phasing out.</p>\n<p>I have recently talked about two sell-side reports that support the bull thesis on Apple shares. Wedbush has&nbsp;just called for the best holiday season&nbsp;in the history of the iPhone, with the segment possibly delivering over $70 billion in revenues in only about three months.</p>\n<p>Just a day earlier,Morgan Stanley put Apple at the center&nbsp;of the metaverse opportunity. According to the research shop, the real catalyst in this important growth story \"comes if or when Apple enters the space\".</p>\n<p><b>What to expect of AAPL</b></p>\n<p>The Apple Maven remains bullish on Apple stock. With valuations having dipped since reaching a 12-month high in early September, shares have become&nbsp;more affordable than some believe them to be.</p>\n<p>That said, and as the all-time high lurks around the corner, investors should set the right expectations. Near peaks, AAPL tends to suffer less from volatility. However, forward one-year returns also tend to be lower than when&nbsp;the stock is bought after a sharp selloff.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Record Level Is Around the Corner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Record Level Is Around the Corner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 23:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/stock/aapl-after-hours-all-time-high-around-corner><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple stock had a strong day of performance on November 17, and is now $3 per share away from the peak. Here is what investors should keep in mind.\nOn Wednesday, November 17, Apple stock climbed ...</p>\n\n<a href=\"https://www.thestreet.com/apple/stock/aapl-after-hours-all-time-high-around-corner\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/aapl-after-hours-all-time-high-around-corner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173100100","content_text":"Apple stock had a strong day of performance on November 17, and is now $3 per share away from the peak. Here is what investors should keep in mind.\nOn Wednesday, November 17, Apple stock climbed nearly 2% to end the trading session valued at about $154 per share, backed by the heaviest trading volume of the month so far. This is the highest that the stock has reached since early September 2021, when the current all-time high of $156.46 was set.\nBelow are a few factors that may be driving bullishness, and what AAPL investors should expect of the stock next.\nThe iPhone\nWhy so bullish?\nApple stock's 1.7% climb on Wednesday was much better than the return of the S&P 500, at a modest loss of 0.3%. Interestingly enough, despite AAPL's strong performance, it was not easy to pinpoint one single cause for the outsized single-day gain.\nMaybe the company's announcement of the Self Service Repair program, to be launched in 2022, had something to do with it. By effectively outsourcing simple services to users, Apple might be able to simplify its service and cost structure.\nHowever, I doubt that this piece of news alone was responsible for creating $40 billion in market value. Instead, I bet that bullishness has been merely a reflection of recent skepticism over the company's ability to perform in the near term phasing out.\nI have recently talked about two sell-side reports that support the bull thesis on Apple shares. Wedbush has just called for the best holiday season in the history of the iPhone, with the segment possibly delivering over $70 billion in revenues in only about three months.\nJust a day earlier,Morgan Stanley put Apple at the center of the metaverse opportunity. According to the research shop, the real catalyst in this important growth story \"comes if or when Apple enters the space\".\nWhat to expect of AAPL\nThe Apple Maven remains bullish on Apple stock. With valuations having dipped since reaching a 12-month high in early September, shares have become more affordable than some believe them to be.\nThat said, and as the all-time high lurks around the corner, investors should set the right expectations. Near peaks, AAPL tends to suffer less from volatility. However, forward one-year returns also tend to be lower than when the stock is bought after a sharp selloff.","news_type":1},"isVote":1,"tweetType":1,"viewCount":38,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871245729,"gmtCreate":1637076529087,"gmtModify":1637076601502,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope this is good union&nbsp;","listText":"Hope this is good union&nbsp;","text":"Hope this is good union","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/871245729","repostId":"1191081895","repostType":4,"repost":{"id":"1191081895","pubTimestamp":1637075626,"share":"https://www.laohu8.com/m/news/1191081895?lang=&edition=full","pubTime":"2021-11-16 23:13","market":"us","language":"en","title":"American Airlines, travel platform Winding Tree announce blockchain partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1191081895","media":"Reuters","summary":"American Airlines(AAL.O)and Swiss travel platform Winding Tree said on Tuesday they have formed a pa","content":"<p>American Airlines(AAL.O)and Swiss travel platform Winding Tree said on Tuesday they have formed a partnership that will enable corporate buyers to access the U.S. airline's data on flights directly, without the need for intermediaries.</p>\n<p>Winding Tree is an Ethereum-based decentralized travel marketplace launched in 2017 that says it aims to make travel cheaper for consumers and more profitable for suppliers.</p>\n<p>Travel agents and corporate travel bookers currently get their data on flights and rooms from global distribution systems (GDS) such as Amadeus and Sabre, which employ real-time inventory technology.</p>\n<p>Winding Tree's platform will allow companies like airlines and hotel operators to publish available inventory directly to those customers.</p>\n<p>\"We're always looking for innovative ways to give our customers access to American's content in the way that's most convenient for them,\" said Neil Geurin, managing director for digital and distribution at American.</p>\n<p>Through the partnership, Winding Tree will provide a framework for American's leisure bookings program with corporate buyers. The program will be able to negotiate unique offers directly with American Airlines</p>\n<p>\"While marketplace connectivity is generic, Ethereum blockchain ensures that each relationship is unique to the private agreement between seller and buyer which enables personalized content pricing between the two parties,\" said Pedro Anderson, chief operating officer and co-founder of Winding Tree.</p>\n<p>Alongside a growing list of partners, American Airlines joins Air Canada in leveraging Winding Tree's decentralized marketplace to deal more directly with buyers.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>American Airlines, travel platform Winding Tree announce blockchain partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmerican Airlines, travel platform Winding Tree announce blockchain partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-16 23:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/finance/american-airlines-travel-platform-winding-tree-announce-blockchain-partnership-2021-11-16/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>American Airlines(AAL.O)and Swiss travel platform Winding Tree said on Tuesday they have formed a partnership that will enable corporate buyers to access the U.S. airline's data on flights directly, ...</p>\n\n<a href=\"https://www.reuters.com/business/finance/american-airlines-travel-platform-winding-tree-announce-blockchain-partnership-2021-11-16/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAL":"美国航空"},"source_url":"https://www.reuters.com/business/finance/american-airlines-travel-platform-winding-tree-announce-blockchain-partnership-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191081895","content_text":"American Airlines(AAL.O)and Swiss travel platform Winding Tree said on Tuesday they have formed a partnership that will enable corporate buyers to access the U.S. airline's data on flights directly, without the need for intermediaries.\nWinding Tree is an Ethereum-based decentralized travel marketplace launched in 2017 that says it aims to make travel cheaper for consumers and more profitable for suppliers.\nTravel agents and corporate travel bookers currently get their data on flights and rooms from global distribution systems (GDS) such as Amadeus and Sabre, which employ real-time inventory technology.\nWinding Tree's platform will allow companies like airlines and hotel operators to publish available inventory directly to those customers.\n\"We're always looking for innovative ways to give our customers access to American's content in the way that's most convenient for them,\" said Neil Geurin, managing director for digital and distribution at American.\nThrough the partnership, Winding Tree will provide a framework for American's leisure bookings program with corporate buyers. The program will be able to negotiate unique offers directly with American Airlines\n\"While marketplace connectivity is generic, Ethereum blockchain ensures that each relationship is unique to the private agreement between seller and buyer which enables personalized content pricing between the two parties,\" said Pedro Anderson, chief operating officer and co-founder of Winding Tree.\nAlongside a growing list of partners, American Airlines joins Air Canada in leveraging Winding Tree's decentralized marketplace to deal more directly with buyers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873888582,"gmtCreate":1636927885280,"gmtModify":1636927885483,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Time for Xmas shopping&nbsp;","listText":"Time for Xmas shopping&nbsp;","text":"Time for Xmas shopping","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873888582","repostId":"1159096163","repostType":4,"repost":{"id":"1159096163","pubTimestamp":1636851053,"share":"https://www.laohu8.com/m/news/1159096163?lang=&edition=full","pubTime":"2021-11-14 08:50","market":"us","language":"en","title":"Shoppers Are Heading to Malls Again. These Stocks Are Good Bets.","url":"https://stock-news.laohu8.com/highlight/detail?id=1159096163","media":"Barrons","summary":"By the time the pandemic hit the U.S. economy, the outlook for Abercrombie & Fitch seemed dire.\nOnce","content":"<p>By the time the pandemic hit the U.S. economy, the outlook for&nbsp;Abercrombie &amp; Fitch&nbsp;seemed dire.</p>\n<p>Once a mall staple that captured the hearts and wallets of teenagers with stark, sexy advertising and dark, perfume-drenched stores, Abercrombie’s (ticker: ANF) stock price hit fresh lows in 2017. Shoppers’ distaste for the brand and a steady decrease in mall traffic clouded its future. Then, in March of 2020, the coronavirus began closing malls and stores across the country.</p>\n<p>The retail apocalypse, it seemed, was about to claim another victim.</p>\n<p>But something surprising happened on the way to the funeral: Abercrombie enjoyed one of its best years since its 2000s heyday. Under CEO Fran Horowitz, the company rebranded, putting out a more inclusive message and pivoting its focus toward young professionals while fine-tuning its Hollister brand for teenagers.</p>\n<p>Revenue increased 24% year over year in the company’s fiscal second quarter ended July 31, and 3% from prepandemic levels. Its stock is up 120% this year as shoppers flush with cash flock back to stores.</p>\n<p>“Perception of a brand is a hard thing to turn, and it takes time in order to build back trust with your consumer,” Horowitz says in an interview with <i>Barron’s</i>. “So, here we are happy to say in 2021 that we are seeing, obviously, the wonderful effects of all of that hard work.”</p>\n<p>Abercrombie isn’t the only retail brand that is coming into a new period of growth. Over the past year, many of America’s retailers have not only clawed their way out of the abyss, but have harnessed macroeconomic changes ushered in by the pandemic to propel themselves into an unexpected renaissance.</p>\n<p>Brands that successfully merged their bricks-and-mortar operations with digital strategies are seeing sales soar and stock prices rise, lifted by a strong market and consumers champing at the bit to spend their pandemic savings. The stock prices of many major mall-based retailers have soared, including&nbsp;Macy’s&nbsp;(M),Nordstrom&nbsp;(JWN), Famous Footwear parent Caleres&nbsp;(CAL), and&nbsp;Signet Jewelers (SIG), which all gained at least 100% in the past 12 months.</p>\n<p>These companies are now poised to reap the benefits of a potentially record-setting holiday season. Consumers could spend $851 billion, a 9.5% increase from last year’s record $777 billion and more than twice the 4.4% average increase over the past five years, according to the National Retail Federation.</p>\n<p>No one knows whether the party will last or whether these stores are simply capturing sales that would have happened in the future. Before retail sales normalize, companies need to navigate a host of supply-chain and inflationary pressures that could put a damper on holiday sales.</p>\n<p>But the unexpected revival has reaffirmed the faith of many brands in the power of the physical stores. While still heavily investing in online operations, they are continuing to bet big on a bricks-and-mortar future. And as investments in physical stores continue, the demise of the bricks-and-mortar retailer that many once expected no longer seems so certain.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/57cd1db2ff23484eff85f5e6ad64d7c8\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Wealthy households plan to spend an average $2,624 this holiday season, 15% more than last year.</span></p>\n<p>The pandemic wasn’t exactly ideal for retailers, but it offered some unique opportunities. The problems were obvious. People were afraid to shop in person. Shoppers—even baby boomers—flocked online in unexpected numbers. Retail behemoths such as&nbsp;Amazon.com&nbsp;(AMZN) and&nbsp;Walmart (WMT) saw their best year ever.</p>\n<p>“The investor sentiment—especially from short term, hedge fund type investors—had just turned very negative on the group,” Columbia Threadneedle Investments retail analyst Mari Shor says. “I just think that investors weren’t really giving the companies, or the consumers, the benefit of the doubt.”</p>\n<p>Shor says the doubt among investors was rooted in the notion that traditional retailers, both prepandemic and postpandemic, wouldn’t make it out alive.</p>\n<p>But the pandemic gave retailers the rare chance to close poorly performing locations and focus on great ones. Many retailers also focused on getting better online, and shifted their sales strategies to target consumers wherever and whenever they wanted to shop—whether online, mobile, or in-store.</p>\n<p>In one example of a company looking to fuel growth while connecting digital and in-store operations, the parent company of Saks Fifth Avenue spun out its e-commerce arm, which is now expected to go public with a target valuation of $6 billion.</p>\n<p>Such approaches proved critical. Online and other non-store sales are expected to increase between 11% and 15% this holiday season, potentially reaching a high of $226 billion, according to National Retail Federation estimates.</p>\n<p>“We’d like to think that the pandemic not only accelerated the adoption of e-commerce around the world but also expanded the market,” says Pedro Palandrani, a research analyst at Global X who covers e-commerce.</p>\n<p>Abercrombie invested hundreds of millions of dollars in its digital strategy, emphasizing smooth transitions from digital to in-store experiences with initiatives such as improving the company’s website and instituting in-store returns and pickups for online purchases. The arrival of the pandemic prompted Abercrombie to close 130 stores worldwide and 50% of the brand’s flagships, bringing total store closures in the past 10 years to about 500, while strategically opening a few key new stores, Horowitz says.</p>\n<p>“Stores matter, but they have to be the right size, the right location, and the right economics,” she says. “You put that together with the digital and it equals magic.”</p>\n<p>Not only are physical stores cost-effective ways to draw in-person shoppers, but they also can serve as crucial distribution centers for online pickups and returns, as well as local shipping, says B. Riley Securities analyst Susan Anderson. In recent years, even online retailers such as Warby Parker (WRBY) have expanded their physical presence to accommodate shopper preferences. “The consumer wants to shop when and where they want to,” Anderson says.</p>\n<p>That behavior can evolve in unexpected ways. Malls and physical stores are growing in popularity among digitally savvy teenagers and young adults.</p>\n<p>According to a survey of 1,000 shoppers earlier this year commissioned by BHDP, a design firm that counts retail among its specialties, 55% of 14-to-17 year olds say they are now shopping at indoor malls, and 90% plan to head to a mall in the next year. The 18-to-24-year-old shoppers surveyed are also back at the mall, trying on products, using in-store promotions, and making returns. Such shifts have led retailers to ditch old views and assumptions about specific demographics, says Rod Sides, vice chairman of U.S. retail and distribution at Deloitte.</p>\n<p>The shifts in strategy during the pandemic put many retailers in a better position for the reopening of malls and downtowns this year—and shoppers were eager to open their wallets.</p>\n<p>During the pandemic, some consumers became unexpectedly flush. They got stimulus payments, saved up from a decline in travel expenses, and saw the markets soar. Today, consumer savings at all income levels are at or near a record. Wealthy households are planning to spend 15% more than last year this holiday season, averaging $2,624 per household and driving much of the season’s growth, an annual Deloitte study found.</p>\n<p>“You got a lot of cash and there’s a fair amount of pent-up demand,” says Mark Zandi, chief economist at Moody’s Analytics.</p>\n<p>Retail and food-services sales increased to an estimated $625 billion in September, up 0.7% from October and 13.9% year over year, according to the U.S. Census Bureau. Sales in retail alone rose 0.8% from August. “We were expecting that you’d see some pullback in September, and we didn’t,” says Citigroup economist Veronica Clark.</p>\n<p>Retailers are much healthier than they were a decade ago heading into the holiday season, Matthew Shay, president and CEO of the National Retail Federation, said in a media briefing in October. A yearly&nbsp;Mastercard&nbsp;spending index forecasts U.S. retail sales to increase 7.4% this season, with significant gains in apparel, department stores, jewelry, and luxury items.</p>\n<p>Luxury retailer&nbsp;Burberry Group&nbsp;(BRBY.UK), known for its tartan fabric and scarves, said this past week that comparable sales for its first half of fiscal 2022 rose 37%, and that full-price sales are growing at a double-digit rate. And&nbsp;Tapestry&nbsp;(TPR), the parent company of Coach, posted better-than-expected fiscal first-quarter earnings, raising its outlook for 2022 sales and profits.</p>\n<p>Some analysts are bullish on the retail sector, with Cowen saying that “many of the luxury brands have successfully been able to take price increases and will likely benefit from the historically strong consumer balance sheets in the U.S. and internationally.” Wolfe Research favors Nordstrom and Tapestry, among others, with analysts writing in a note that “nearly all the major drivers of U.S. consumer spending favor the high end.”</p>\n<p>Meanwhile, more Americans started coming out to the mall. Placer.ai mall-traffic statistics show that foot traffic for indoor malls was up 3% in October compared with 2019 levels, and traffic for outdoor malls was up 5%—one of the reasons mall stores are seeing their stocks soar. Simon Property Group (SPG), which owns the malls themselves, saw its stock gain about 90% in 2021.</p>\n<p>“With the combination of more individuals becoming fully vaccinated, paired with many shopping early for the coming holiday season due to supply-chain concerns, we have seen a steady rise in foot traffic since July,” says Lindsay Petak, senior marketing manager for Tysons Corner Center in the Washington region. The mall is owned by Macerich (MAC), which also has seen its share price nearly double this year.</p>\n<p>All of this added to a stock run-up for the ages for beaten-down retailers. Over the past year, the&nbsp;SPDR S&amp;P Retail&nbsp;exchanged-trade fund (XRT) was up 85%, while the S&amp;P 500 rose 33%. The&nbsp;Invesco S&amp;P 500 Equal Weight Consumer Discretionary&nbsp;ETF (RCD) has outperformed the S&amp;P 500 by five percentage points this year, a sign that investors remain bullish on retail sales.</p>\n<p>“We’ve seen department stores and apparel and discretionary retailers really bounce back as soon as the economy reopened,” the NRF’s Shay says. “Department stores are always a popular destination for the holiday season, based on the consumer survey work we do....They continue to be at the top of the list of the places people shop this year.”</p>\n<p>All that said, analysts and investors alike remain confident of the role physical stores play, which might look different from their online counterparts, but they’re here to stay.</p>\n<p>The verdict on whether the retail renaissance is sustainable in the long term isn’t in yet. Retailers are operating in a macroeconomic environment far from the norm, making any guesses even more speculative.</p>\n<p>“I don’t think we have normal insight yet because there are just too many complexities throughout the business right now,” says Jefferies analyst Janine Stichter.</p>\n<p>Companies are struggling to manage ongoing supply-chain concerns, inflationary pressures, and a persistent labor shortage, which are likely to bite into earnings despite all signs pointing to a strong holiday quarter. “The supply-chain issues, they’re real,” Horowitz says.</p>\n<p>Abercrombie is assuming a modest impact on sales due to supply-chain constraints, with even bigger impacts coming from freight inflation, the company said in its second-quarter earnings call.</p>\n<p>To ease supply-chain pressures, retailers are encouraging consumers to start their shopping early—a trend that could skew end-of-year sales data, Citigroup’s Clark says. If shoppers pull their gift-buying forward, there could be a decline in November and December compared with previous years. “It’s not necessarily that spending is much weaker; it’s just that the distribution over months is different,” she says.</p>\n<p>On the flip side, low inventories will give retailers higher pricing power that can help offset supply-chain disruptions, Stichter says. While beneficial to retailers, this could drive prices up even more, says Sasha Tomic, an economist at Boston College.</p>\n<p>Whatever the risks, strong performance won’t last forever, says Matthew Forester, chief investment officer at BNY Mellon’s Lockwood Advisors. “The U.S. economy, overall, is clearly slowing down,” he says. “And we’re going to slow down into the next year. Plus, as we get back to trend growth, that’s just what’s likely to happen.”</p>\n<p>The economy will eventually exit its euphoria as stimulus continues to dwindle, he says. And while the comedown might not be “terrible,” he says, it will still be a decline from where consumer spending is now.</p>\n<p>Abercrombie, though, is powering through the headwinds with the help of its bricks-and-mortar stores. The company is planning to position more inventory in stores, and is routing e-commerce orders to stores as well as partnering with Uber, Shipt, and Postmates to offer same-day delivery.</p>\n<p>Other retailers have taken supply-chain solutions in their own hands. Specialty-apparel company American Eagle Outfitters (AEO) recently announced it was acquiring Quiet Logistics, an operator of automated distribution centers near city centers, just weeks after it bought AirTerra, which focuses on middle-mile logistics—the delivery of products from a warehouse to a retail store.</p>\n<p>“We’re going to just continue at it,” Horowitz says.</p>\n<p>As retailers forge ahead, doomsayers might have to hold off on heralding a retail apocalypse. For now, the sentiment is clear: Consumers are rediscovering the joys of bricks-and-mortar shopping. The mall has become cool again.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shoppers Are Heading to Malls Again. These Stocks Are Good Bets.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShoppers Are Heading to Malls Again. These Stocks Are Good Bets.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-14 08:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/macys-abercrombie-simon-property-retail-stocks-51636674171?mod=hp_HERO><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By the time the pandemic hit the U.S. economy, the outlook for Abercrombie & Fitch seemed dire.\nOnce a mall staple that captured the hearts and wallets of teenagers with stark, sexy advertising and ...</p>\n\n<a href=\"https://www.barrons.com/articles/macys-abercrombie-simon-property-retail-stocks-51636674171?mod=hp_HERO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TPR":"Tapestry Inc.","WMT":"沃尔玛","CAL":"Caleres鞋业","BRBY.UK":"巴宝莉","ANF":"爱芬奇","M":"梅西百货","JWN":"诺德斯特龙","AMZN":"亚马逊","BBRYF":"Burberry Group Plc","RCD":"Invesco S&P 500 Equal Weight Consumer Discretionary ETF","SIG":"西格内特珠宝"},"source_url":"https://www.barrons.com/articles/macys-abercrombie-simon-property-retail-stocks-51636674171?mod=hp_HERO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159096163","content_text":"By the time the pandemic hit the U.S. economy, the outlook for Abercrombie & Fitch seemed dire.\nOnce a mall staple that captured the hearts and wallets of teenagers with stark, sexy advertising and dark, perfume-drenched stores, Abercrombie’s (ticker: ANF) stock price hit fresh lows in 2017. Shoppers’ distaste for the brand and a steady decrease in mall traffic clouded its future. Then, in March of 2020, the coronavirus began closing malls and stores across the country.\nThe retail apocalypse, it seemed, was about to claim another victim.\nBut something surprising happened on the way to the funeral: Abercrombie enjoyed one of its best years since its 2000s heyday. Under CEO Fran Horowitz, the company rebranded, putting out a more inclusive message and pivoting its focus toward young professionals while fine-tuning its Hollister brand for teenagers.\nRevenue increased 24% year over year in the company’s fiscal second quarter ended July 31, and 3% from prepandemic levels. Its stock is up 120% this year as shoppers flush with cash flock back to stores.\n“Perception of a brand is a hard thing to turn, and it takes time in order to build back trust with your consumer,” Horowitz says in an interview with Barron’s. “So, here we are happy to say in 2021 that we are seeing, obviously, the wonderful effects of all of that hard work.”\nAbercrombie isn’t the only retail brand that is coming into a new period of growth. Over the past year, many of America’s retailers have not only clawed their way out of the abyss, but have harnessed macroeconomic changes ushered in by the pandemic to propel themselves into an unexpected renaissance.\nBrands that successfully merged their bricks-and-mortar operations with digital strategies are seeing sales soar and stock prices rise, lifted by a strong market and consumers champing at the bit to spend their pandemic savings. The stock prices of many major mall-based retailers have soared, including Macy’s (M),Nordstrom (JWN), Famous Footwear parent Caleres (CAL), and Signet Jewelers (SIG), which all gained at least 100% in the past 12 months.\nThese companies are now poised to reap the benefits of a potentially record-setting holiday season. Consumers could spend $851 billion, a 9.5% increase from last year’s record $777 billion and more than twice the 4.4% average increase over the past five years, according to the National Retail Federation.\nNo one knows whether the party will last or whether these stores are simply capturing sales that would have happened in the future. Before retail sales normalize, companies need to navigate a host of supply-chain and inflationary pressures that could put a damper on holiday sales.\nBut the unexpected revival has reaffirmed the faith of many brands in the power of the physical stores. While still heavily investing in online operations, they are continuing to bet big on a bricks-and-mortar future. And as investments in physical stores continue, the demise of the bricks-and-mortar retailer that many once expected no longer seems so certain.\nWealthy households plan to spend an average $2,624 this holiday season, 15% more than last year.\nThe pandemic wasn’t exactly ideal for retailers, but it offered some unique opportunities. The problems were obvious. People were afraid to shop in person. Shoppers—even baby boomers—flocked online in unexpected numbers. Retail behemoths such as Amazon.com (AMZN) and Walmart (WMT) saw their best year ever.\n“The investor sentiment—especially from short term, hedge fund type investors—had just turned very negative on the group,” Columbia Threadneedle Investments retail analyst Mari Shor says. “I just think that investors weren’t really giving the companies, or the consumers, the benefit of the doubt.”\nShor says the doubt among investors was rooted in the notion that traditional retailers, both prepandemic and postpandemic, wouldn’t make it out alive.\nBut the pandemic gave retailers the rare chance to close poorly performing locations and focus on great ones. Many retailers also focused on getting better online, and shifted their sales strategies to target consumers wherever and whenever they wanted to shop—whether online, mobile, or in-store.\nIn one example of a company looking to fuel growth while connecting digital and in-store operations, the parent company of Saks Fifth Avenue spun out its e-commerce arm, which is now expected to go public with a target valuation of $6 billion.\nSuch approaches proved critical. Online and other non-store sales are expected to increase between 11% and 15% this holiday season, potentially reaching a high of $226 billion, according to National Retail Federation estimates.\n“We’d like to think that the pandemic not only accelerated the adoption of e-commerce around the world but also expanded the market,” says Pedro Palandrani, a research analyst at Global X who covers e-commerce.\nAbercrombie invested hundreds of millions of dollars in its digital strategy, emphasizing smooth transitions from digital to in-store experiences with initiatives such as improving the company’s website and instituting in-store returns and pickups for online purchases. The arrival of the pandemic prompted Abercrombie to close 130 stores worldwide and 50% of the brand’s flagships, bringing total store closures in the past 10 years to about 500, while strategically opening a few key new stores, Horowitz says.\n“Stores matter, but they have to be the right size, the right location, and the right economics,” she says. “You put that together with the digital and it equals magic.”\nNot only are physical stores cost-effective ways to draw in-person shoppers, but they also can serve as crucial distribution centers for online pickups and returns, as well as local shipping, says B. Riley Securities analyst Susan Anderson. In recent years, even online retailers such as Warby Parker (WRBY) have expanded their physical presence to accommodate shopper preferences. “The consumer wants to shop when and where they want to,” Anderson says.\nThat behavior can evolve in unexpected ways. Malls and physical stores are growing in popularity among digitally savvy teenagers and young adults.\nAccording to a survey of 1,000 shoppers earlier this year commissioned by BHDP, a design firm that counts retail among its specialties, 55% of 14-to-17 year olds say they are now shopping at indoor malls, and 90% plan to head to a mall in the next year. The 18-to-24-year-old shoppers surveyed are also back at the mall, trying on products, using in-store promotions, and making returns. Such shifts have led retailers to ditch old views and assumptions about specific demographics, says Rod Sides, vice chairman of U.S. retail and distribution at Deloitte.\nThe shifts in strategy during the pandemic put many retailers in a better position for the reopening of malls and downtowns this year—and shoppers were eager to open their wallets.\nDuring the pandemic, some consumers became unexpectedly flush. They got stimulus payments, saved up from a decline in travel expenses, and saw the markets soar. Today, consumer savings at all income levels are at or near a record. Wealthy households are planning to spend 15% more than last year this holiday season, averaging $2,624 per household and driving much of the season’s growth, an annual Deloitte study found.\n“You got a lot of cash and there’s a fair amount of pent-up demand,” says Mark Zandi, chief economist at Moody’s Analytics.\nRetail and food-services sales increased to an estimated $625 billion in September, up 0.7% from October and 13.9% year over year, according to the U.S. Census Bureau. Sales in retail alone rose 0.8% from August. “We were expecting that you’d see some pullback in September, and we didn’t,” says Citigroup economist Veronica Clark.\nRetailers are much healthier than they were a decade ago heading into the holiday season, Matthew Shay, president and CEO of the National Retail Federation, said in a media briefing in October. A yearly Mastercard spending index forecasts U.S. retail sales to increase 7.4% this season, with significant gains in apparel, department stores, jewelry, and luxury items.\nLuxury retailer Burberry Group (BRBY.UK), known for its tartan fabric and scarves, said this past week that comparable sales for its first half of fiscal 2022 rose 37%, and that full-price sales are growing at a double-digit rate. And Tapestry (TPR), the parent company of Coach, posted better-than-expected fiscal first-quarter earnings, raising its outlook for 2022 sales and profits.\nSome analysts are bullish on the retail sector, with Cowen saying that “many of the luxury brands have successfully been able to take price increases and will likely benefit from the historically strong consumer balance sheets in the U.S. and internationally.” Wolfe Research favors Nordstrom and Tapestry, among others, with analysts writing in a note that “nearly all the major drivers of U.S. consumer spending favor the high end.”\nMeanwhile, more Americans started coming out to the mall. Placer.ai mall-traffic statistics show that foot traffic for indoor malls was up 3% in October compared with 2019 levels, and traffic for outdoor malls was up 5%—one of the reasons mall stores are seeing their stocks soar. Simon Property Group (SPG), which owns the malls themselves, saw its stock gain about 90% in 2021.\n“With the combination of more individuals becoming fully vaccinated, paired with many shopping early for the coming holiday season due to supply-chain concerns, we have seen a steady rise in foot traffic since July,” says Lindsay Petak, senior marketing manager for Tysons Corner Center in the Washington region. The mall is owned by Macerich (MAC), which also has seen its share price nearly double this year.\nAll of this added to a stock run-up for the ages for beaten-down retailers. Over the past year, the SPDR S&P Retail exchanged-trade fund (XRT) was up 85%, while the S&P 500 rose 33%. The Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RCD) has outperformed the S&P 500 by five percentage points this year, a sign that investors remain bullish on retail sales.\n“We’ve seen department stores and apparel and discretionary retailers really bounce back as soon as the economy reopened,” the NRF’s Shay says. “Department stores are always a popular destination for the holiday season, based on the consumer survey work we do....They continue to be at the top of the list of the places people shop this year.”\nAll that said, analysts and investors alike remain confident of the role physical stores play, which might look different from their online counterparts, but they’re here to stay.\nThe verdict on whether the retail renaissance is sustainable in the long term isn’t in yet. Retailers are operating in a macroeconomic environment far from the norm, making any guesses even more speculative.\n“I don’t think we have normal insight yet because there are just too many complexities throughout the business right now,” says Jefferies analyst Janine Stichter.\nCompanies are struggling to manage ongoing supply-chain concerns, inflationary pressures, and a persistent labor shortage, which are likely to bite into earnings despite all signs pointing to a strong holiday quarter. “The supply-chain issues, they’re real,” Horowitz says.\nAbercrombie is assuming a modest impact on sales due to supply-chain constraints, with even bigger impacts coming from freight inflation, the company said in its second-quarter earnings call.\nTo ease supply-chain pressures, retailers are encouraging consumers to start their shopping early—a trend that could skew end-of-year sales data, Citigroup’s Clark says. If shoppers pull their gift-buying forward, there could be a decline in November and December compared with previous years. “It’s not necessarily that spending is much weaker; it’s just that the distribution over months is different,” she says.\nOn the flip side, low inventories will give retailers higher pricing power that can help offset supply-chain disruptions, Stichter says. While beneficial to retailers, this could drive prices up even more, says Sasha Tomic, an economist at Boston College.\nWhatever the risks, strong performance won’t last forever, says Matthew Forester, chief investment officer at BNY Mellon’s Lockwood Advisors. “The U.S. economy, overall, is clearly slowing down,” he says. “And we’re going to slow down into the next year. Plus, as we get back to trend growth, that’s just what’s likely to happen.”\nThe economy will eventually exit its euphoria as stimulus continues to dwindle, he says. And while the comedown might not be “terrible,” he says, it will still be a decline from where consumer spending is now.\nAbercrombie, though, is powering through the headwinds with the help of its bricks-and-mortar stores. The company is planning to position more inventory in stores, and is routing e-commerce orders to stores as well as partnering with Uber, Shipt, and Postmates to offer same-day delivery.\nOther retailers have taken supply-chain solutions in their own hands. Specialty-apparel company American Eagle Outfitters (AEO) recently announced it was acquiring Quiet Logistics, an operator of automated distribution centers near city centers, just weeks after it bought AirTerra, which focuses on middle-mile logistics—the delivery of products from a warehouse to a retail store.\n“We’re going to just continue at it,” Horowitz says.\nAs retailers forge ahead, doomsayers might have to hold off on heralding a retail apocalypse. For now, the sentiment is clear: Consumers are rediscovering the joys of bricks-and-mortar shopping. The mall has become cool again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862804978,"gmtCreate":1632864740834,"gmtModify":1632864741003,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Well done! Any digital will grow in this pandemic times","listText":"Well done! Any digital will grow in this pandemic times","text":"Well done! Any digital will grow in this pandemic times","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862804978","repostId":"1186367782","repostType":4,"repost":{"id":"1186367782","pubTimestamp":1632844664,"share":"https://www.laohu8.com/m/news/1186367782?lang=&edition=full","pubTime":"2021-09-28 23:57","market":"us","language":"en","title":"Digital optimization software company Amplitude spikes 43% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186367782","media":"Barrons","summary":"Digital optimization software company Amplitude spikes 43% on its first day of trading.\n\nThe Nasdaq ","content":"<p>Digital optimization software company Amplitude spikes 43% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/62694ef6f6a7c9121cf7a7ecdeb81f76\" tg-width=\"1404\" tg-height=\"893\" width=\"100%\" height=\"auto\"></p>\n<p>The Nasdaq&nbsp;assigned a $35 reference price&nbsp;to Amplitude, the data analytics company going public Tuesday.</p>\n<p>With 102.7 million shares outstanding, Amplitude will have a near $3.6 billion market cap based on the $35 reference price. This is below the $4 billion valuation Amplitude snagged&nbsp;with its $150 million round in June. It will trade on the Nasdaq under the symbol AMPL.</p>\n<p>Amplitude is not selling shares with the direct listing. Instead, stockholders are offering 35,398,389 shares of Class A stock for resale,a prospectus said.</p>\n<p>Reference prices typically have no relevance as to how the stock will trade. Rather, they are meant to be a guide that informs the public of recent private trading activity.Coinbase Global(ticker: COIN), which went public in April using a direct listing,received a $250 reference price. Its stock opened at $381. In May,Squarespace(SQSP)&nbsp;received a $50 reference price and&nbsp;its stock opened at $48.</p>\n<p>Founded in 2012, Amplitude provides data analytic software that helps companies gain insight into customer behavior. It has more than 1,200 customers including&nbsp;Walmart(WMT), NBC, Burger King,Ford(F),Twitter(TWTR),Dropbox(DBDX) and&nbsp;Paypal Holdings(PYPL).</p>\n<p>Amplitude is not profitable. The startup reported $16.5 million in losses for the six months ended June 30 compared to $16.6 million in losses for the same time period in 2020. Revenue rose 57% to about $72.4 million.</p>\n<p>Spenser Skates and Curtis Liu, Amplitude co-founders, have each registered one million shares in the direct listing, the prospectus said. But this doesn’t mean Skates, who is CEO, or Liu, who is chief technology officer, will sell their stock. (Jeffrey Wang, the third co-founder, is not listed as offering shares.)</p>\n<p>Amplitude is the fifth company this year to go public using a direct listing. The other companies that have used a DL are&nbsp;Roblox(RBLX),Coinbase,Squarespace(SQSP), and&nbsp;ZipRecruiter(ZIP). Warby Parker, the trendy eyewear brand, will also&nbsp;begin trading Wednesday&nbsp;using a direct listing.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Digital optimization software company Amplitude spikes 43% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDigital optimization software company Amplitude spikes 43% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 23:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amplitude-set-to-go-public-tuesday-51632781178?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Digital optimization software company Amplitude spikes 43% on its first day of trading.\n\nThe Nasdaq assigned a $35 reference price to Amplitude, the data analytics company going public Tuesday.\nWith ...</p>\n\n<a href=\"https://www.barrons.com/articles/amplitude-set-to-go-public-tuesday-51632781178?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMPL":"AmplitudeE, Inc."},"source_url":"https://www.barrons.com/articles/amplitude-set-to-go-public-tuesday-51632781178?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186367782","content_text":"Digital optimization software company Amplitude spikes 43% on its first day of trading.\n\nThe Nasdaq assigned a $35 reference price to Amplitude, the data analytics company going public Tuesday.\nWith 102.7 million shares outstanding, Amplitude will have a near $3.6 billion market cap based on the $35 reference price. This is below the $4 billion valuation Amplitude snagged with its $150 million round in June. It will trade on the Nasdaq under the symbol AMPL.\nAmplitude is not selling shares with the direct listing. Instead, stockholders are offering 35,398,389 shares of Class A stock for resale,a prospectus said.\nReference prices typically have no relevance as to how the stock will trade. Rather, they are meant to be a guide that informs the public of recent private trading activity.Coinbase Global(ticker: COIN), which went public in April using a direct listing,received a $250 reference price. Its stock opened at $381. In May,Squarespace(SQSP) received a $50 reference price and its stock opened at $48.\nFounded in 2012, Amplitude provides data analytic software that helps companies gain insight into customer behavior. It has more than 1,200 customers including Walmart(WMT), NBC, Burger King,Ford(F),Twitter(TWTR),Dropbox(DBDX) and Paypal Holdings(PYPL).\nAmplitude is not profitable. The startup reported $16.5 million in losses for the six months ended June 30 compared to $16.6 million in losses for the same time period in 2020. Revenue rose 57% to about $72.4 million.\nSpenser Skates and Curtis Liu, Amplitude co-founders, have each registered one million shares in the direct listing, the prospectus said. But this doesn’t mean Skates, who is CEO, or Liu, who is chief technology officer, will sell their stock. (Jeffrey Wang, the third co-founder, is not listed as offering shares.)\nAmplitude is the fifth company this year to go public using a direct listing. The other companies that have used a DL are Roblox(RBLX),Coinbase,Squarespace(SQSP), and ZipRecruiter(ZIP). Warby Parker, the trendy eyewear brand, will also begin trading Wednesday using a direct listing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693002445,"gmtCreate":1639919653697,"gmtModify":1639919654073,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Get yourself vaccinated&nbsp;","listText":"Get yourself vaccinated&nbsp;","text":"Get yourself vaccinated","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693002445","repostId":"2192790540","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606034327,"gmtCreate":1638800487278,"gmtModify":1638800487539,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Fly high high&nbsp;","listText":"Fly high high&nbsp;","text":"Fly high high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/606034327","repostId":"1125140621","repostType":4,"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877403923,"gmtCreate":1637966706645,"gmtModify":1637966983417,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"That explains why the oil companies are falling like durian after a storm","listText":"That explains why the oil companies are falling like durian after a storm","text":"That explains why the oil companies are falling like durian after a storm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877403923","repostId":"1158420182","repostType":4,"repost":{"id":"1158420182","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637939738,"share":"https://www.laohu8.com/m/news/1158420182?lang=&edition=full","pubTime":"2021-11-26 23:15","market":"fut","language":"en","title":"WTI crude tumbled 9.02% to $71.28 a barrel, Brent fell 8.16%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1158420182","media":"Tiger Newspress","summary":"WTI crude tumbled 9.02% to $71.28 a barrel, Brent fell 8.16%.","content":"<p>WTI crude tumbled&nbsp;9.02% to $71.28 a barrel,&nbsp;Brent&nbsp;fell&nbsp;8.16%.<img src=\"https://static.tigerbbs.com/6e118e6a5e909412e48ca104b2c37b30\" tg-width=\"884\" tg-height=\"611\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/1ac1680f3b9d8085d5fd9b6a868ce9c3\" tg-width=\"870\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WTI crude tumbled 9.02% to $71.28 a barrel, Brent fell 8.16%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWTI crude tumbled 9.02% to $71.28 a barrel, Brent fell 8.16%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-26 23:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WTI crude tumbled&nbsp;9.02% to $71.28 a barrel,&nbsp;Brent&nbsp;fell&nbsp;8.16%.<img src=\"https://static.tigerbbs.com/6e118e6a5e909412e48ca104b2c37b30\" tg-width=\"884\" tg-height=\"611\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/1ac1680f3b9d8085d5fd9b6a868ce9c3\" tg-width=\"870\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158420182","content_text":"WTI crude tumbled 9.02% to $71.28 a barrel, Brent fell 8.16%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879080510,"gmtCreate":1636670652540,"gmtModify":1636670653040,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Timing to buy","listText":"Timing to buy","text":"Timing to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879080510","repostId":"1152431554","repostType":4,"repost":{"id":"1152431554","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636642592,"share":"https://www.laohu8.com/m/news/1152431554?lang=&edition=full","pubTime":"2021-11-11 22:56","market":"us","language":"en","title":"Disney shares fell more than 8% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1152431554","media":"Tiger Newspress","summary":"Atlantic Equities is cutting Disney to Neutral from Buy in the wake of its earnings, pointing to direct-to-consumer additionsslowing more than expected.It is lowering its price target to $172 from $219 per share, just below the last closing price.\"Disney's focus on franchises led to excellent sign-up rates out of the gate, but we are increasingly convinced that the penetration of this fan base is close to saturated in launched markets,\" analyst Hamilton Faber writes in a note.\"While there are ne","content":"<p>Disney&nbsp;shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;8%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/17f05b19cd1d11648dfa9756186272f4\" tg-width=\"874\" tg-height=\"611\" width=\"100%\" height=\"auto\"></p>\n<p>Atlantic Equities is cutting Disney&nbsp;to Neutral from Buy in the wake of its earnings, pointing to direct-to-consumer additionsslowing more than expected.</p>\n<p>It is lowering its price target to $172 from $219 per share, just below the last closing price.</p>\n<p>\"Disney's focus on franchises led to excellent sign-up rates out of the gate, but we are increasingly convinced that the penetration of this fan base is close to saturated in launched markets,\" analyst Hamilton Faber writes in a note.</p>\n<p>\"While there are new geographies to come, we believe volume growth will disappoint,\" Faber says. \"We are retaining our (sum of the parts) valuation but cutting our target DTC revenue multiple from 8x to 5x.\"</p>\n<p>Faber adds that reiterated Disney+ subscriber guidance of 230-260M subs for 2024 looks aggressive and he is cutting his estimate slightly to 218M.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney shares fell more than 8% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney shares fell more than 8% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-11 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Disney&nbsp;shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;8%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/17f05b19cd1d11648dfa9756186272f4\" tg-width=\"874\" tg-height=\"611\" width=\"100%\" height=\"auto\"></p>\n<p>Atlantic Equities is cutting Disney&nbsp;to Neutral from Buy in the wake of its earnings, pointing to direct-to-consumer additionsslowing more than expected.</p>\n<p>It is lowering its price target to $172 from $219 per share, just below the last closing price.</p>\n<p>\"Disney's focus on franchises led to excellent sign-up rates out of the gate, but we are increasingly convinced that the penetration of this fan base is close to saturated in launched markets,\" analyst Hamilton Faber writes in a note.</p>\n<p>\"While there are new geographies to come, we believe volume growth will disappoint,\" Faber says. \"We are retaining our (sum of the parts) valuation but cutting our target DTC revenue multiple from 8x to 5x.\"</p>\n<p>Faber adds that reiterated Disney+ subscriber guidance of 230-260M subs for 2024 looks aggressive and he is cutting his estimate slightly to 218M.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152431554","content_text":"Disney shares fell more than 8% in morning trading.\nAtlantic Equities is cutting Disney to Neutral from Buy in the wake of its earnings, pointing to direct-to-consumer additionsslowing more than expected.\nIt is lowering its price target to $172 from $219 per share, just below the last closing price.\n\"Disney's focus on franchises led to excellent sign-up rates out of the gate, but we are increasingly convinced that the penetration of this fan base is close to saturated in launched markets,\" analyst Hamilton Faber writes in a note.\n\"While there are new geographies to come, we believe volume growth will disappoint,\" Faber says. \"We are retaining our (sum of the parts) valuation but cutting our target DTC revenue multiple from 8x to 5x.\"\nFaber adds that reiterated Disney+ subscriber guidance of 230-260M subs for 2024 looks aggressive and he is cutting his estimate slightly to 218M.","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}